<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Environ Res Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Int J Environ Res Public Health</journal-id><journal-id journal-id-type="publisher-id">ijerph</journal-id><journal-title-group><journal-title>International Journal of Environmental Research and Public Health</journal-title></journal-title-group><issn pub-type="ppub">1661-7827</issn><issn pub-type="epub">1660-4601</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7459861</article-id><article-id pub-id-type="doi">10.3390/ijerph17165648</article-id><article-id pub-id-type="publisher-id">ijerph-17-05648</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0106-8050</contrib-id><name><surname>Hozhabri</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="af1-ijerph-17-05648">1</xref></contrib><contrib contrib-type="author"><name><surname>Piceci Sparascio</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="af1-ijerph-17-05648">1</xref><xref ref-type="aff" rid="af2-ijerph-17-05648">2</xref></contrib><contrib contrib-type="author"><name><surname>Sohrabi</surname><given-names>Hamidreza</given-names></name><xref ref-type="aff" rid="af3-ijerph-17-05648">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2187-7592</contrib-id><name><surname>Mousavifar</surname><given-names>Leila</given-names></name><xref ref-type="aff" rid="af4-ijerph-17-05648">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5638-7302</contrib-id><name><surname>Roy</surname><given-names>Ren&#x000e9;</given-names></name><xref ref-type="aff" rid="af4-ijerph-17-05648">4</xref><xref ref-type="aff" rid="af5-ijerph-17-05648">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2901-265X</contrib-id><name><surname>Scribano</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="af6-ijerph-17-05648">6</xref><xref ref-type="aff" rid="af7-ijerph-17-05648">7</xref><xref rid="c1-ijerph-17-05648" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4408-8062</contrib-id><name><surname>De Luca</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="af2-ijerph-17-05648">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2163-1613</contrib-id><name><surname>Ambrosi</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="af8-ijerph-17-05648">8</xref><xref ref-type="author-notes" rid="fn1-ijerph-17-05648">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5726-2090</contrib-id><name><surname>Sarshar</surname><given-names>Meysam</given-names></name><xref ref-type="aff" rid="af9-ijerph-17-05648">9</xref><xref ref-type="aff" rid="af10-ijerph-17-05648">10</xref><xref ref-type="aff" rid="af11-ijerph-17-05648">11</xref><xref rid="c1-ijerph-17-05648" ref-type="corresp">*</xref><xref ref-type="author-notes" rid="fn1-ijerph-17-05648">&#x02020;</xref></contrib></contrib-group><aff id="af1-ijerph-17-05648"><label>1</label>Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy; <email>hossein.hozhabri@uniroma1.it</email> (H.H.); <email>francesca.piceci@uniroma1.it</email> (F.P.S.)</aff><aff id="af2-ijerph-17-05648"><label>2</label>Medical Genetics Division, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy; <email>a.deluca@css-mendel.it</email></aff><aff id="af3-ijerph-17-05648"><label>3</label>Department of Veterinary Science, University of Turin, 10095 Grugliasco, Italy; <email>hamidreza.sohrabi@edu.unito.it</email></aff><aff id="af4-ijerph-17-05648"><label>4</label>Department of Chemistry, Universit&#x000e9; du Qu&#x000e9;bec &#x000e0; Montr&#x000e9;al, P.O. Box 8888, Succ. Centre-Ville, Montr&#x000e9;al, QC H3C 3P8, Canada; <email>mousavifar.seyedehleila@uqam.ca</email> (L.M.); <email>roy.rene@uqam.ca</email> (R.R.)</aff><aff id="af5-ijerph-17-05648"><label>5</label>INRS-Institut Armand-Frappier, Universit&#x000e9; du Qu&#x000e9;bec, 531 boul. des Prairies, Laval, QC H7V 1B7, Canada</aff><aff id="af6-ijerph-17-05648"><label>6</label>Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy</aff><aff id="af7-ijerph-17-05648"><label>7</label>Dani Di Gi&#x000f2; Foundation-Onlus, 00193 Rome, Italy</aff><aff id="af8-ijerph-17-05648"><label>8</label>IRCCS San Raffaele Pisana, Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy; <email>cecilia.ambrosi@uniroma5.it</email></aff><aff id="af9-ijerph-17-05648"><label>9</label>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory affiliated to Institute Pasteur Italia- Cenci Bolognetti Foundation, 00185 Rome, Italy</aff><aff id="af10-ijerph-17-05648"><label>10</label>Research Laboratories, Bambino Ges&#x000f9; Children&#x02019;s Hospital, IRCCS, 00146 Rome, Italy</aff><aff id="af11-ijerph-17-05648"><label>11</label>Microbiology Research Center (MRC), Pasteur Institute of Iran, 1316943551 Tehran, Iran</aff><author-notes><corresp id="c1-ijerph-17-05648"><label>*</label>Correspondence: <email>daniela.scribano@uniroma1.it</email> (D.S.); <email>meysam.sarshar@uniroma1.it</email> (M.S.)</corresp><fn id="fn1-ijerph-17-05648"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2020</year></pub-date><volume>17</volume><issue>16</issue><elocation-id>5648</elocation-id><history><date date-type="received"><day>04</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Over the past two decades, there have been two major outbreaks where the crossover of animal <italic>Betacoronaviruses</italic> to humans has resulted in severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). In December 2019, a global public health concern started with the emergence of a new strain of coronavirus (SARS-CoV-2 or 2019 novel coronavirus, 2019-nCoV) which has rapidly spread all over the world from its origin in Wuhan, China. SARS-CoV-2 belongs to the <italic>Betacoronavirus</italic> genus, which includes human SARS-CoV, MERS and two other human coronaviruses (HCoVs), HCoV-OC43 and HCoV-HKU1. The fatality rate of SARS-CoV-2 is lower than the two previous coronavirus epidemics, but it is faster spreading and the large number of infected people with severe viral pneumonia and respiratory illness, showed SARS-CoV-2 to be highly contagious. Based on the current published evidence, herein we summarize the origin, genetics, epidemiology, clinical manifestations, preventions, diagnosis and up to date treatments of SARS-CoV-2 infections in comparison with those caused by SARS-CoV and MERS-CoV. Moreover, the possible impact of weather conditions on the transmission of SARS-CoV-2 is also discussed. Therefore, the aim of the present review is to reconsider the two previous pandemics and provide a reference for future studies as well as therapeutic approaches.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>epidemiology</kwd><kwd>transmission</kwd><kwd>temperature and humidity</kwd><kwd>COVID-19</kwd><kwd>pneumonia</kwd><kwd>diagnosis</kwd><kwd>ACE2</kwd><kwd>inhibitors</kwd><kwd>therapeutics strategies</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijerph-17-05648"><title>1. Introduction</title><sec id="sec1dot1-ijerph-17-05648"><title>1.1. What Are Coronaviruses</title><p>Coronaviruses (CoVs) are a group of highly enveloped viruses that are diversely found in humans and wildlife. With their high mutation rate and infectivity, CoVs are important zoonotic pathogens that can infect animals [<xref rid="B1-ijerph-17-05648" ref-type="bibr">1</xref>,<xref rid="B2-ijerph-17-05648" ref-type="bibr">2</xref>] and humans, leading to 5&#x02013;10% of acute respiratory syndromes [<xref rid="B3-ijerph-17-05648" ref-type="bibr">3</xref>]. Apart from infecting a variety of economically important vertebrates (such as pigs and chickens), six species have been identified to cause disease in humans [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>]. They are known to infect respiratory, gastrointestinal, hepatic and neurologic systems with a wide range of clinical features from asymptomatic course to severe disease that require hospitalization in the intensive care unit [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>,<xref rid="B5-ijerph-17-05648" ref-type="bibr">5</xref>]. The first human coronaviruses (HCoVs), HCoV-229E and OC43, shown to be significant respiratory pathogens, were identified in the 1960s [<xref rid="B6-ijerph-17-05648" ref-type="bibr">6</xref>,<xref rid="B7-ijerph-17-05648" ref-type="bibr">7</xref>]. However, it is assumed that the first recorded coronavirus-related disease was feline infectious peritonitis (FIP) in 1912 [<xref rid="B8-ijerph-17-05648" ref-type="bibr">8</xref>]. The &#x0201c;corona&#x0201d;-like or crown-like morphology of these viruses leads to choose the name &#x0201c;coronavirus,&#x0201d; in 1968 [<xref rid="B6-ijerph-17-05648" ref-type="bibr">6</xref>].</p><p>Coronaviruses were not considered as highly pathogenic for humans before the beginning of the 21st century. Afterward, two highly pathogenic HCoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), emerging from animal reservoirs, have led to global epidemics of deadly pneumonia in humans with high morbidity and mortality [<xref rid="B9-ijerph-17-05648" ref-type="bibr">9</xref>,<xref rid="B10-ijerph-17-05648" ref-type="bibr">10</xref>]. In December 2019, seven years after MERS outbreak, the third pathogenic HCoV emerged in Wuhan, the capital city of Hubei province in China, causing severe pneumonia [<xref rid="B11-ijerph-17-05648" ref-type="bibr">11</xref>,<xref rid="B12-ijerph-17-05648" ref-type="bibr">12</xref>]. Considered as agents that are a great public health threat, an epidemiological alert was placed by the World Health Organization (WHO) and this new coronavirus was named SARS-CoV-2 and the related respiratory disease COVID-19 (<uri xlink:href="https://www.who.int">https://www.who.int</uri>). Compared with SARS-CoV, SARS-CoV-2 appears to be more readily transmitted from human-to-human, spreading to multiple continents and the outbreak of SARS-CoV-2 was declared on January 30, 2020 [<xref rid="B13-ijerph-17-05648" ref-type="bibr">13</xref>] (<uri xlink:href="https://www.who.int">https://www.who.int</uri>). In this review, we will introduce the current knowledge on the origin and evolution of SARS-CoV-2, emphasizing its characteristics and its genetic diversity from previous coronaviruses, with a brief comment on its epidemiology and pathogenesis. We also highlight the environmental factors involved in virus transmission. Knowledge about this novel coronavirus is rapidly evolving, and efforts must be implemented in order to protect the populations by reducing transmission and controlling the spread of this fatal disease.</p></sec><sec id="sec1dot2-ijerph-17-05648"><title>1.2. Origin, Family Member, Diversity and Taxonomy of Coronaviruses</title><p>According to the International Committee on Taxonomy of Viruses, CoVs are classified under the order of <italic>Nidovirales</italic>, a family of <italic>Coronaviridae</italic> and subfamily of <italic>Coronavirinae</italic> [<xref rid="B14-ijerph-17-05648" ref-type="bibr">14</xref>]. Based on previous serologic and recent genomic evidences, the family of <italic>Coronaviridae</italic> encompasses two subfamilies: subfamily <italic>Orthocoronavirinae</italic> and subfamily <italic>Torovirinae</italic> (<xref ref-type="fig" rid="ijerph-17-05648-f001">Figure 1</xref>) [<xref rid="B7-ijerph-17-05648" ref-type="bibr">7</xref>,<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>]. The subfamily of <italic>Orthocoronavirinae</italic> consists of four genera: <italic>Alphacoronavirus</italic>, <italic>Betacoronavirus</italic>, <italic>Gammacoronavirus</italic> and <italic>Deltacoronavirus</italic> [<xref rid="B7-ijerph-17-05648" ref-type="bibr">7</xref>,<xref rid="B16-ijerph-17-05648" ref-type="bibr">16</xref>,<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>].</p><p>CoVs can be isolated from different animal species, including birds, livestock and mammals such as camels, bats, masked palm civets, mice, dogs and cats [<xref rid="B18-ijerph-17-05648" ref-type="bibr">18</xref>,<xref rid="B19-ijerph-17-05648" ref-type="bibr">19</xref>]. Animal CoVs are known to cause acute diseases in several animals and could be responsible for economic losses in domestic animals or birds [<xref rid="B20-ijerph-17-05648" ref-type="bibr">20</xref>,<xref rid="B21-ijerph-17-05648" ref-type="bibr">21</xref>]. Domestic animals may play an important role as intermediate hosts that enable virus transmission from one species to humans [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>]. The genera <italic>Gamma</italic>- and <italic>Deltacoronavirus</italic> infect birds, but some of them can also infect mammals [<xref rid="B16-ijerph-17-05648" ref-type="bibr">16</xref>]. These animal CoVs include transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), avian infectious bronchitis virus (IBV)&#x02014;and more recently&#x02014;swine acute diarrhea syndrome coronavirus (SADS-CoV). However, animal CoVs can also infect humans that can spread the infection through human-to-human transmission [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>,<xref rid="B22-ijerph-17-05648" ref-type="bibr">22</xref>]. On the other hand, <italic>Alpha</italic>- and <italic>Betacoronavirus</italic> infect only mammals and usually cause respiratory illness in humans; among these, strains 229E, OC43, HKU1 and NL63 are the most widespread infecting young children, infants as well as elderly individuals [<xref rid="B23-ijerph-17-05648" ref-type="bibr">23</xref>,<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B25-ijerph-17-05648" ref-type="bibr">25</xref>]. The high rates of mutation characterizing all RNA viruses [<xref rid="B23-ijerph-17-05648" ref-type="bibr">23</xref>,<xref rid="B26-ijerph-17-05648" ref-type="bibr">26</xref>], the evolving nature of CoVs and the simplicity of transmission from one species to another are the most relevant features learned from SARS-CoV and MERS-CoV previous outbreaks [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B23-ijerph-17-05648" ref-type="bibr">23</xref>,<xref rid="B25-ijerph-17-05648" ref-type="bibr">25</xref>]. Importantly, most of <italic>Alpha</italic>- and <italic>Betacoronavirus</italic> were found only in bats, and many genetically diverse coronaviruses phylogenetically related to SARS-CoV and MERS-CoV have been discovered in diverse bat species worldwide [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>]. Therefore, HCoVs such as SARS- and MERS-CoVs seem to have originated in bats by sequential mutations and recombination, including those occurring in the intermediate hosts, civets and raccoon dogs for SARS-CoV and camels in the case of MERS-CoV, finally acquiring the ability to infect humans [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>]. Comparative genome studies published in recent papers strongly support the hypothesis that SARS-CoV-2 originated in bats and that pangolins (Manis javanica) acted as intermediate mammalian hosts [<xref rid="B11-ijerph-17-05648" ref-type="bibr">11</xref>,<xref rid="B27-ijerph-17-05648" ref-type="bibr">27</xref>] (<xref ref-type="fig" rid="ijerph-17-05648-f002">Figure 2</xref>). Indeed, the genetic sequence of the SARS-CoV-2 showed more than 79% nucleotide identity with the sequence of SARS-CoV and 50% with MERS-CoV [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>,<xref rid="B19-ijerph-17-05648" ref-type="bibr">19</xref>]. The high degree of homology of the angiotensin-converting enzyme 2 (ACE2) receptor in several animal species can be considered as an additional evidence to support that SARS-CoV-2 originated from bats [<xref rid="B28-ijerph-17-05648" ref-type="bibr">28</xref>]. Based on findings from molecular studies, the ACE2 proteins of non-human primates, pigs, cats and ferrets closely resemble the human ACE2 receptor. Therefore, these species may be susceptible to SARS-CoV-2 infection, as has been shown for SARS-CoV. Although a recent study showed that neither pigs nor chickens are susceptible to SARS-CoV-2 by intranasal or oculo-oronasal infections, more evidences are needed to exclude pigs as intermediate host of SARS-CoV-2 [<xref rid="B29-ijerph-17-05648" ref-type="bibr">29</xref>].</p><p>Based on the genetic sequence identity and the phylogenetic reports, SARS-CoV-2 is sufficiently different from SARS-CoV; thus, WHO has classified it as a new <italic>Betacoronavirus</italic> that infects humans [<xref rid="B30-ijerph-17-05648" ref-type="bibr">30</xref>].</p></sec><sec id="sec1dot3-ijerph-17-05648"><title>1.3. Morphology and Genomic Structure of HCoVs</title><p>The genome of HCoVs is a single-stranded positive-sense RNA (+ssRNA) (~26&#x02013;32 kb) with 5&#x02032;-cap structure and 3&#x02032;-poly A tail, which is among the largest known RNA genomes [<xref rid="B31-ijerph-17-05648" ref-type="bibr">31</xref>,<xref rid="B32-ijerph-17-05648" ref-type="bibr">32</xref>,<xref rid="B33-ijerph-17-05648" ref-type="bibr">33</xref>]. The typical HCoVs gene order is 5&#x02032;-replicase-S-E-M-N-3&#x02032;, with numerous (6 to 11) open reading frames (ORFs) encoding accessory proteins scattered among the structural genes [<xref rid="B34-ijerph-17-05648" ref-type="bibr">34</xref>,<xref rid="B35-ijerph-17-05648" ref-type="bibr">35</xref>]. The first ORFs (ORF1a and 1b) comprise two-thirds (approximately 67%) of the genome length and encode 16 nonstructural polyproteins (nsps 1&#x02013;16) and are directly translated from the genomic RNA [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>]. There is a &#x02212;1 ribosomal frameshift between ORF1a and ORF1b, leading to the production of two large replicase polypeptides (pp): pp1a and pp1ab. These polypeptides are further processed by two virally encoded cysteine proteases, the papain-like protease (PLpro) and a 3-chymotrypsin-like protease (3CLpro) into 16 nsps [<xref rid="B3-ijerph-17-05648" ref-type="bibr">3</xref>,<xref rid="B33-ijerph-17-05648" ref-type="bibr">33</xref>,<xref rid="B36-ijerph-17-05648" ref-type="bibr">36</xref>]. There are at least four structural proteins encoded by the coronaviral genome: a spike glycoprotein (S), an envelope protein (E), a membrane protein (M) and nucleocapsid protein (N) with short untranslated regions at both termini, required to produce a structurally complete viral particle [<xref rid="B37-ijerph-17-05648" ref-type="bibr">37</xref>]. The typical coronavirus virion structure and proteins are shown in <xref ref-type="fig" rid="ijerph-17-05648-f003">Figure 3</xref>. The M protein is in higher quantities in comparison to any other proteins in the virus particle; with its three transmembrane domains, it shapes virions, promotes membrane curvature and binds to the nucleocapsid [<xref rid="B38-ijerph-17-05648" ref-type="bibr">38</xref>,<xref rid="B39-ijerph-17-05648" ref-type="bibr">39</xref>]. The N protein contains two domains, both of which can bind to nsp3 protein to help tether the genome to replication&#x02013;transcription complex (RTC) and package viral RNA into the viral particle during viral assembly [<xref rid="B39-ijerph-17-05648" ref-type="bibr">39</xref>,<xref rid="B40-ijerph-17-05648" ref-type="bibr">40</xref>]. The E protein is involved in virus assembly and virion release from host cells, while the S protein plays a vital role in attachment to host receptors, viral entry and determines host tropism [<xref rid="B41-ijerph-17-05648" ref-type="bibr">41</xref>,<xref rid="B42-ijerph-17-05648" ref-type="bibr">42</xref>]. Additionally, some coronaviruses, such as HCoV-OC43 and HCoV-HKU1, have a hemagglutinin-esterase (HE) gene between ORF1b and S [<xref rid="B43-ijerph-17-05648" ref-type="bibr">43</xref>,<xref rid="B44-ijerph-17-05648" ref-type="bibr">44</xref>,<xref rid="B45-ijerph-17-05648" ref-type="bibr">45</xref>,<xref rid="B46-ijerph-17-05648" ref-type="bibr">46</xref>]. This hemagglutinin, like the influenza homolog enzyme, binds to sialic acid on host cell-surface glycoproteins and possesses acetyl-esterase activity [<xref rid="B47-ijerph-17-05648" ref-type="bibr">47</xref>]. Besides coronavirus-conserved genes, the SARS-CoV, SARS-CoV-2 and MERS-CoV genomes contain several specific accessory genes including ORF3a/b, 4a/b, ORF5, ORF6, ORF7a/b, ORF8a/b and 9b (<xref ref-type="fig" rid="ijerph-17-05648-f004">Figure 4</xref>) [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>,<xref rid="B48-ijerph-17-05648" ref-type="bibr">48</xref>,<xref rid="B49-ijerph-17-05648" ref-type="bibr">49</xref>]. All the structural and accessory proteins are translated from subgenomic RNAs (sgRNAs) generated during genome transcription/replication of CoVs [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>].</p></sec><sec id="sec1dot4-ijerph-17-05648"><title>1.4. Attachment, Entry and Life Cycle of HCoVs</title><p>Attachment, cell entry, translation of viral replicase, genome replication, translation of structural proteins and virion assembly and release are the phases of coronavirus replication cycle [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>,<xref rid="B50-ijerph-17-05648" ref-type="bibr">50</xref>]. SARS-CoV, MERS-CoV and SARS-CoV-2 bind to different host receptors to gain entry into host cells [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>,<xref rid="B51-ijerph-17-05648" ref-type="bibr">51</xref>,<xref rid="B52-ijerph-17-05648" ref-type="bibr">52</xref>]. Viral entry is mediated by the transmembrane S glycoprotein that comprises two functional subunits (S1 and S2 subunits) responsible for receptor recognition and viral-host cell membranes fusion, respectively [<xref rid="B53-ijerph-17-05648" ref-type="bibr">53</xref>,<xref rid="B54-ijerph-17-05648" ref-type="bibr">54</xref>]. S1 receptor-binding domain (RBD) mediates binding to the cognate host cell receptor; however, the S2 domain mediates the fusion events, between viral envelope and host cell membrane [<xref rid="B52-ijerph-17-05648" ref-type="bibr">52</xref>,<xref rid="B55-ijerph-17-05648" ref-type="bibr">55</xref>,<xref rid="B56-ijerph-17-05648" ref-type="bibr">56</xref>]. As recently found, SARS-CoV-2 uses the same ACE2 receptor [<xref rid="B57-ijerph-17-05648" ref-type="bibr">57</xref>], as SARS-CoV, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4, also known as CD26) receptor (<xref rid="ijerph-17-05648-t001" ref-type="table">Table 1</xref>) [<xref rid="B58-ijerph-17-05648" ref-type="bibr">58</xref>]. The fusion of the S protein to the plasma membrane of host cell generates a double membrane vesicle in the host cell, thereby allowing release of the nucleocapsid into the cytoplasm, followed by genome transcription [<xref rid="B53-ijerph-17-05648" ref-type="bibr">53</xref>,<xref rid="B54-ijerph-17-05648" ref-type="bibr">54</xref>]. Upon entry into the cell, virus-specific RNA and proteins are synthesized, probably entirely in the cytoplasm. Translation starts with the expression of two polyproteins, pp1a and pp1ab, which undergo co-translational proteolytic processing into the proteins that form the replicase complex. This complex is used to transcribe a 3&#x02032;-coterminal set of nested subgenomic mRNAs, as well as genomic RNA that have a common 5&#x02032; &#x0201c;leader&#x0201d; sequence derived from the 5&#x02032; end of the genome. New virions are assembled by budding into intracellular membranes of the pre-Golgi compartment and released through the cell secretory mechanisms [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>,<xref rid="B42-ijerph-17-05648" ref-type="bibr">42</xref>,<xref rid="B48-ijerph-17-05648" ref-type="bibr">48</xref>,<xref rid="B50-ijerph-17-05648" ref-type="bibr">50</xref>].</p></sec></sec><sec id="sec2-ijerph-17-05648"><title>2. Pathogenesis and Mode of Transmission</title><p>Virologic as well as genetic studies have demonstrated that bats are reservoir hosts of both SARS-CoV and MERS-CoV, but also that they can use other species as intermediate hosts before spreading to humans [<xref rid="B59-ijerph-17-05648" ref-type="bibr">59</xref>,<xref rid="B60-ijerph-17-05648" ref-type="bibr">60</xref>]. The detection of two genomes distinct from known swine in ill piglets were reported by two independent groups [<xref rid="B61-ijerph-17-05648" ref-type="bibr">61</xref>,<xref rid="B62-ijerph-17-05648" ref-type="bibr">62</xref>]. The phylogenetic analyses showed that these novel swine enteric <italic>Alphacoronaviruses</italic> (SeACoVs) were strongly related to the <italic>Rhinolophus</italic> bat coronavirus HKU2 isolated in Guangdong Province, in southern China [<xref rid="B61-ijerph-17-05648" ref-type="bibr">61</xref>,<xref rid="B62-ijerph-17-05648" ref-type="bibr">62</xref>]. This suggests that coronaviruses of bat origin may have &#x02018;jumped&#x02019; the barrier of the species to infect pigs as intermediate hosts. The CD26 receptor sequence alignment between humans and pigs demonstrates a 94.5% overlap, which is sufficient for the possible cross-species transmission [<xref rid="B63-ijerph-17-05648" ref-type="bibr">63</xref>]. It has also been documented that pigs are susceptible to human SARS-CoV [<xref rid="B64-ijerph-17-05648" ref-type="bibr">64</xref>] and MERS-CoV infections [<xref rid="B65-ijerph-17-05648" ref-type="bibr">65</xref>]. The large number of mutations within the RBD enabled viruses to infect new hosts, representing a potential threat for both animal and human health. In southern China, the unique climate, the high density of domestic as well as wild pigs, along with the extensive bat distribution and carriage of tremendous quantities of recombinant novel coronaviruses may result in the appearance of more novel coronaviruses in the future [<xref rid="B66-ijerph-17-05648" ref-type="bibr">66</xref>]. It is generally acknowledged that numerous viruses have existed and were restricted to their natural reservoirs for lengthy times [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>]. The consistent spillover of viruses from natural hosts to humans and other species is essentially related to human activities, including urbanization and modern agricultural practices, leading to the constant human exposure to the ever-changing mutant CoVs from their reservoirs [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>]. The close contact between humans and animals and the practice of eating raw meat are both risk factors for causing a new human CoV outbreak [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>]. Hence, COVID-19 should be considered as a zoonotic disease that spread from animals to humans.</p><p>Following the first SARS-CoV-2 outbreak in seafood and wildlife market in Wuhan, secondary cases started to be identified after ten days. Although these new patients did not have any contact with the market, they had a history of contact with people who attended the market [<xref rid="B60-ijerph-17-05648" ref-type="bibr">60</xref>]. Therefore, similarly to SARS-CoV and unlikely to MERS-CoV, human-to-human transmission for SARS-CoV-2 has been reported and is currently considered as the main type of transmission worldwide [<xref rid="B5-ijerph-17-05648" ref-type="bibr">5</xref>,<xref rid="B19-ijerph-17-05648" ref-type="bibr">19</xref>]. On January 13, 2020, Thailand announced the first non-Chinese case of infection that spread from the Chinese provinces, to the Asian continent [<xref rid="B60-ijerph-17-05648" ref-type="bibr">60</xref>]. This case was a Chinese tourist who has traveled to Thailand and did not have any epidemiological link to the market [<xref rid="B30-ijerph-17-05648" ref-type="bibr">30</xref>]. More recently, Forster et al., by using phylogenetic analysis based on nucleotide mutations of 160 complete human SARS-CoV-2 genomes found that three variants of SARS-CoV-2 (A as the ancestral type, plus B and C) represent the bat outgroup coronaviruses. In particular, the A and C types were found mostly in European- American patients, whereas the B type was common in East Asia suggesting that this kind of analysis could help in following the evolution of SARS-CoV-2 [<xref rid="B67-ijerph-17-05648" ref-type="bibr">67</xref>].</p><sec><title>Human-to-Human Transmission and Viral Reservoir</title><p>It was demonstrated that SARS-CoVs have adapted themselves to bind to human ACE2 receptor and infect human cells effectively [<xref rid="B68-ijerph-17-05648" ref-type="bibr">68</xref>]. This form of adaptation required a series of amino acid changes in the RBD within the S protein of SARS viruses that circulated in bats [<xref rid="B56-ijerph-17-05648" ref-type="bibr">56</xref>,<xref rid="B68-ijerph-17-05648" ref-type="bibr">68</xref>]. Therefore, the human-to-human transmission that was seen in the course of the SARS-CoV outbreaks is directly attributable to the ability of SARS-CoVs to adapt their S protein to efficiently bind to human ACE2, thus infecting ciliated bronchial epithelial cells and type II pneumocytes [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B69-ijerph-17-05648" ref-type="bibr">69</xref>]. Similar to SARS-CoV, ACE2 is also used by SARS-CoV-2 as the entry receptor in the ACE2-expressing cells, suggesting that SARS-CoV-2 has a life cycle similar to SARS-CoV [<xref rid="B56-ijerph-17-05648" ref-type="bibr">56</xref>,<xref rid="B68-ijerph-17-05648" ref-type="bibr">68</xref>]. As outlined before, SARS-CoV S protein regulates the receptor binding and membrane fusion activities determining host tropism and transmission capacity. Several evidences highlighted a higher binding affinity of SARS-CoV-2 RBD to the ACE2 receptor. In particular, molecular and in silico analyses demonstrated that SARS-CoV-2 RBD conformation and amino acid composition enhance the bonding between the S protein and ACE2 receptor [<xref rid="B51-ijerph-17-05648" ref-type="bibr">51</xref>,<xref rid="B70-ijerph-17-05648" ref-type="bibr">70</xref>,<xref rid="B71-ijerph-17-05648" ref-type="bibr">71</xref>]. A recent biophysical and structural analysis of the SARS-CoV-2 S protein showed that it binds to ACE2 receptor with about 10- to 20-fold higher affinity than the S protein of SARS-CoV [<xref rid="B52-ijerph-17-05648" ref-type="bibr">52</xref>,<xref rid="B72-ijerph-17-05648" ref-type="bibr">72</xref>]. This high affinity could account for its extreme infectivity among human populations. Another feature of the powerful infectivity of SARS-CoV-2 is that the shedding pattern of viral particles in SARS-CoV-2 diagnosed patients is similar to that of influenza patients in which viral loads at the time of symptom onset are higher and gradually decrease within days; interestingly, this pattern seems to be different from that reported for SARS-CoV patients where the highest shedding is reported 10 days after the onset of symptoms [<xref rid="B20-ijerph-17-05648" ref-type="bibr">20</xref>,<xref rid="B73-ijerph-17-05648" ref-type="bibr">73</xref>,<xref rid="B74-ijerph-17-05648" ref-type="bibr">74</xref>]. These results indicate that SARS-CoV-2 can spread more easily than SARS-CoV in the community even in the absence of symptoms or when only initial mild symptoms are present [<xref rid="B75-ijerph-17-05648" ref-type="bibr">75</xref>].</p><p>The human-to-human transmission of SARS-CoV-2 mainly occurs by inhalation of respiratory droplets spread by coughing or sneezing from an infected individual, but also by direct contact of contaminated surfaces and then touching the nose, mouth and eyes [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>,<xref rid="B77-ijerph-17-05648" ref-type="bibr">77</xref>,<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>]. The virus was shown to remain stable in favorable atmospheric conditions on different surfaces for days [<xref rid="B79-ijerph-17-05648" ref-type="bibr">79</xref>]. Additionally, transmission in an unventilated environment or closed spaces due to high aerosol concentrations has been suggested [<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>,<xref rid="B77-ijerph-17-05648" ref-type="bibr">77</xref>]. In agreement, the presence of SARS-CoV-2 in the surfaces of the houses of confirmed patients was reported, further strengthening this mode of contact transmission. Moreover, live viruses were also found in the stool of COVID-19 patients, as previously found for both SARS-CoV and MERS-CoV [<xref rid="B77-ijerph-17-05648" ref-type="bibr">77</xref>]. Given its capacity for survival in feces and the expression of ACE2 within intestine, it was demonstrated that SARS-CoV-2 can infect these tissues and can be released in feces; therefore, water supply contamination and fecal-oral route transmission is also hypothesized [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B80-ijerph-17-05648" ref-type="bibr">80</xref>]. However, at present, there have not been reported cases of fecal-oral transmission of the virus. Studies have also indicated that SARS-CoV-2 transmission via ocular surfaces should not be overlooked, as contaminated droplets and body fluids could easily infect the human conjunctival epithelium [<xref rid="B81-ijerph-17-05648" ref-type="bibr">81</xref>]. SARS-CoV-2 is also responsible for cluster transmission, in particular within family clusters [<xref rid="B77-ijerph-17-05648" ref-type="bibr">77</xref>]. In some cities, 50% to 80% of all reported cases of COVID-19 accounted for cluster transmission [<xref rid="B82-ijerph-17-05648" ref-type="bibr">82</xref>]. Based on the current information, there is no evidence for transplacental transmission from infected pregnant women to their fetus, who underwent caesarean section [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>]. Therefore, whether transmission during vaginal birth can occur remains to be established, neonatal COVID-19 disease as postnatal transmission was documented [<xref rid="B83-ijerph-17-05648" ref-type="bibr">83</xref>]. Although, SARS-CoV-2 may definitely infect infants, it has been reported that neonates, infants and children develop significantly milder forms of the disease than their adult counterparts [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B84-ijerph-17-05648" ref-type="bibr">84</xref>].</p></sec></sec><sec id="sec3-ijerph-17-05648"><title>3. Epidemiology</title><p>Coronaviruses are responsible for 5&#x02013;10% of acute respiratory illness while it has been estimated that 2% of the population is deemed as an asymptomatic carrier of these viruses. The first discovered HCoV was IBV that causes respiratory disease in human whereas, HCoV-229E and HCoV-OC43, which cause the common cold in humans [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B26-ijerph-17-05648" ref-type="bibr">26</xref>,<xref rid="B85-ijerph-17-05648" ref-type="bibr">85</xref>]. They were not considered to be highly pathogenic for humans until the outbreak of SARS in Guangdong state of China in 2002 and 2003. SARS-CoV infected more than 8000 people worldwide and caused 916 deaths (<xref rid="ijerph-17-05648-t002" ref-type="table">Table 2</xref>), representing a mortality rate by around 10% [<xref rid="B86-ijerph-17-05648" ref-type="bibr">86</xref>]. Ten years later in 2012, MERS-CoV emerged in Saudi Arabia and infected over 2494 people with 858 deaths, accounting for a mortality rate approximately of 35% [<xref rid="B9-ijerph-17-05648" ref-type="bibr">9</xref>,<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B87-ijerph-17-05648" ref-type="bibr">87</xref>]. Starting in China in December 2019, there were reports of patients presenting severe viral pneumonia [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B88-ijerph-17-05648" ref-type="bibr">88</xref>,<xref rid="B89-ijerph-17-05648" ref-type="bibr">89</xref>]. This public health concern resulted in many unknown pneumonia cases who were admitted to local hospitals [<xref rid="B22-ijerph-17-05648" ref-type="bibr">22</xref>,<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>] (<uri xlink:href="https://www.who.int">https://www.who.int</uri>). Primary etiologic investigations performed in those patients showed that they were epidemiologically linked to a Huanan wholesale seafood market that also traded live animals and wildlife [<xref rid="B17-ijerph-17-05648" ref-type="bibr">17</xref>,<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B90-ijerph-17-05648" ref-type="bibr">90</xref>]. By January 7th, 2020 Chinese authorities announced that a new type of coronavirus was isolated [<xref rid="B60-ijerph-17-05648" ref-type="bibr">60</xref>,<xref rid="B91-ijerph-17-05648" ref-type="bibr">91</xref>]. The epicenter of infection was probably linked to a zoonotic pathogen being present in the seafood and exotic animal wholesale market [<xref rid="B60-ijerph-17-05648" ref-type="bibr">60</xref>,<xref rid="B91-ijerph-17-05648" ref-type="bibr">91</xref>]. The rapid increasing numbers and rate of fatalities indicated a second mode of transmission, from human-to-human, that allowed viral spreading primarily in other Asian countries such as South Korea and Iran followed by many countries such as Italy, Spain, Germany, France, Brazil and USA [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B60-ijerph-17-05648" ref-type="bibr">60</xref>]. It is very intriguing to note that the SARS epidemic in southern China in 2002 and the current outbreak of COVID-19 had peaked in mid-February due to exposure to live animals sold in markets. Furthermore, similar to the SARS outbreak, this epidemic has occurred during the Spring Festival in China, as the most famous traditional countrywide festival in China, gathering nearly three billion people from different areas. These favorable conditions caused the wide transmission of this fatal pneumonia and severe difficulties for disease control and prevention of the epidemic [<xref rid="B92-ijerph-17-05648" ref-type="bibr">92</xref>].</p><p>Based on clinical data of diagnosed patients during the SARS-CoV-2 outbreak, the basic reproduction number (R0) is estimated to range between 2 and 6.47 in various modeling studies [<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>,<xref rid="B93-ijerph-17-05648" ref-type="bibr">93</xref>]. The SARS-CoV-2 R0 is in line with the one estimated for SARS-CoVs and MERS-CoVs (from 2 to 5) [<xref rid="B94-ijerph-17-05648" ref-type="bibr">94</xref>,<xref rid="B95-ijerph-17-05648" ref-type="bibr">95</xref>]. Currently, increasing countries are experiencing clusters of cases and community transmission following SARS-CoV-2 pandemic. Since its emergence, the COVID-19 has drawn well-deserved attention from authorities in order to protect their community and stop or slow down transmission of this disease. At the time of this review, according to the daily report of the World Health Organization, SARS-CoV-2 has affected over 17,889,134 people with around 228,611 daily new cases and killed more than 686,145 people all over the world, by August 3rd, 2020 (the up to date fatality rate is reported from <uri xlink:href="https://covid19.who.int">https://covid19.who.int</uri>). We must take into consideration that these data are relative to laboratories and clinically confirmed cases while the actual number including asymptomatic cases, infected undiagnosed and death patients would be much higher than reported cases.</p><sec><title>The Possible Effects of Weather Conditions on the Transmission of SARS-CoV-2</title><p>The transmission of seasonal respiratory coronaviruses can be affected by several climate parameters such as temperature and humidity [<xref rid="B96-ijerph-17-05648" ref-type="bibr">96</xref>]. Therefore, understanding the relationship between weather and transmission of COVID-19 is the key to forecast the intensity and end time of this pandemic. To this regard, emerging evidence suggests that whether climate conditions may influence the transmission of the SARS-CoV-2 by boosting the spread (much of the data have not been peer-reviewed yet). To date, COVID-19 has had a significant expansion in the Northern Hemisphere (NH) belt, given that it covers cities and populated areas; conversely, in the belt of the Southern Hemisphere (SH), which covers very low population and landless areas, COVID-19 has not been reported yet.</p><p>Based on climate and ERA-interim reanalysis dataset in NH belt from November 2019 to March 2020, we compared the average rate of humidity and temperature between five cities in European Countries with significant community transmission of COVID-19 versus five cities of North Africa which are expected to be less exposed to COVID-19. The information recorded by the meteorological stations has been used, since these are more accurate than satellite data [<xref rid="B97-ijerph-17-05648" ref-type="bibr">97</xref>]. As shown in <xref rid="ijerph-17-05648-t003" ref-type="table">Table 3</xref>, the average amount of humidity is very close between European and African selected sites. The main reason is the proximity of these cities to the Mediterranean Sea coastline. In addition, the north wind, which blows from northern Europe to European cities (ECs), increases the humidity of these cities. Conversely, there are temperature differences between considered ECs and North African cities (<xref rid="ijerph-17-05648-t003" ref-type="table">Table 3</xref>). Thus, temperature and humidity should be considered parameters involved in the transmission of COVID-19. Up to know, few studies have investigated the association of temperature and humidity with COVID-19 incidence and death rates. The first meteorological study was done in 100 different Chinese cities each having more than 40 cases of COVID-19 in a 3-day period during the end of January [<xref rid="B98-ijerph-17-05648" ref-type="bibr">98</xref>]. This group showed that high temperature and humidity significantly reduces the transmission of COVID-19. Their results indicate that the increases of 1 &#x000b0;C in temperature and 1% in relative humidity lower R by 0.0225 and 0.0158, respectively [<xref rid="B98-ijerph-17-05648" ref-type="bibr">98</xref>]. A preprint study on confirmed COVID-19 cases collected from 429 cities showed that every 1 &#x000b0;C increase in the minimum temperature of higher-temperature cities reduced the disease incidence and death rates by 0.86 [<xref rid="B99-ijerph-17-05648" ref-type="bibr">99</xref>]. Another preprint study suggested that the average increase of 1 &#x000b0;C in temperature correlates negatively with the predicted number of cases worldwide [<xref rid="B100-ijerph-17-05648" ref-type="bibr">100</xref>]. These results are in accordance with Wu Y et al. who showed that among all confirmed COVID-19 new cases and new deaths from 166 countries (excluding China), a 1 &#x000b0;C increase in temperature is associated with a 3.08% reduction in daily new cases and a 1.19% reduction in daily new deaths, whereas a 1% increase in relative humidity was associated with a 0.85% reduction in daily new cases and a 0.51% reduction in daily new deaths [<xref rid="B101-ijerph-17-05648" ref-type="bibr">101</xref>]. A recent study conducted in Italy showed a positive correlation of SARS-CoV-2 spreading and weather conditions including temperatures ranging 4&#x02013;12 &#x000b0;C and relative humidity of 60&#x02013;80% [<xref rid="B102-ijerph-17-05648" ref-type="bibr">102</xref>]. In a geographic and population modeling study conducted in five largest cities in Colombia, the transmission of SARS-CoV-2 seems to be comodulated by temperature and humidity. Their observation revealed a strong reduction of transmission in climates with temperatures above 30 &#x000b0;C and relative humidity below 78% which may comodulate the infectivity of SARS-CoV-2 within respiratory droplets [<xref rid="B103-ijerph-17-05648" ref-type="bibr">103</xref>].</p><p>Overall, these meteorological analyses support that the combination of temperature and humidity could represent a direct influence on the transmission of the COVID-19. It can be assumed that the arrival of summer and rainy season in the NH can effectively reduce the transmission of the COVID-19. The distribution of COVID-19 across different longitudes and latitudes with a range of temperatures and humidity may help to predict the prevalence of this disease in terms of environmental characteristics. This could lead to a better understanding of how the virus spreads around the world (<xref ref-type="fig" rid="ijerph-17-05648-f005">Figure 5</xref>). It should be noted that apart from the capability of SARS-CoV-2 to persist on environmental surfaces under favorable atmospheric conditions, the duration of its persistence may be affected by temperature and humidity. However, caution is needed when considering the implications of these findings, which may be subject to confounding. Although warmer climates may slow the spread of SARS-CoV-2, relying on weather changes alone to slow the transmission of COVID-19 are unlikely to be enough. However, using this type of dataset and climate analysis modeling is possible to identify areas that are most likely to be at risk of significant COVID-19 cases in the future and serve as an alarm signal to various government departments and agencies to adopt the necessary measures to prevent virus spread [<xref rid="B104-ijerph-17-05648" ref-type="bibr">104</xref>]. Moreover, more data are gathering around the world due to the change of the season and all authors agree that the association between temperature/humidity and SARS-CoV-2 is an appreciable hypothesis, but not a certainty yet.</p></sec></sec><sec id="sec4-ijerph-17-05648"><title>4. Clinical Presentations</title><p>The most common symptoms of patients at onset of COVID-19 disease are defined as fever, dry cough, fatigue and less often, symptoms of sputum production, headache, sore throat, myalgia; hemoptysis, dyspnea, diarrhea and lymphopenia were also observed [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>,<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B28-ijerph-17-05648" ref-type="bibr">28</xref>] (<xref ref-type="fig" rid="ijerph-17-05648-f006">Figure 6</xref>). The spectrum of clinical features of COVID-19 has been found ranging from an asymptomatic state to severe respiratory failure and multiorgan dysfunction [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>]. Symptomatic people are considered to be more contagious, similar to most viral-related respiratory diseases. However, individuals who remain asymptomatic may also transmit the virus and cases infected by an asymptomatic individual in the prodrome period of COVID-19 have also been reported [<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>]. Asymptomatic infections can occur because of weakened immune responses and subclinical manifestations or also because the virus is waiting for opportunities to invade and reproduce. A recent study has shown that a viral load detected in an asymptomatic patient was just like to the one observed in symptomatic patients, indicating the capability of transmission in asymptomatic patients [<xref rid="B74-ijerph-17-05648" ref-type="bibr">74</xref>]. According to disease presentation, COVID-19 can be classified as mild, moderate, severe and critical (<xref rid="ijerph-17-05648-t004" ref-type="table">Table 4</xref>) [<xref rid="B57-ijerph-17-05648" ref-type="bibr">57</xref>,<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>,<xref rid="B105-ijerph-17-05648" ref-type="bibr">105</xref>].</p><p>The symptoms of SARS-CoV-2 infection appear after an incubation period of 1 to 14 days, similar to those of SARS- and MERS-CoV infections (median approximately 5.2 days in different studies) and 95% of patients are likely to experience symptoms within 12.5 days from contact [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B106-ijerph-17-05648" ref-type="bibr">106</xref>,<xref rid="B107-ijerph-17-05648" ref-type="bibr">107</xref>,<xref rid="B108-ijerph-17-05648" ref-type="bibr">108</xref>]. However, in an asymptomatic carrier the incubation period was 19 days, complicating the challenge to contain the outbreak [<xref rid="B109-ijerph-17-05648" ref-type="bibr">109</xref>]. The median time between onset of symptoms and dyspnea is 5 days, 7 days for hospitalization and 8 days for acute respiratory distress syndrome (ARDS) (<xref ref-type="fig" rid="ijerph-17-05648-f007">Figure 7</xref>) [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>] (<uri xlink:href="https://www.epicentro.iss.it/coronavirus/sars-cov-2">https://www.epicentro.iss.it/coronavirus/sars-cov-2</uri>). Patients at this stage in intensive care unit (ICU) with quarantine facilities may require mechanical ventilation. Moreover, bacterial infections can cause a secondary pneumonia [<xref rid="B108-ijerph-17-05648" ref-type="bibr">108</xref>]. In addition, the period from the beginning of COVID-19 symptoms to death varied between 6 and 41 days with an average of 14 days [<xref rid="B110-ijerph-17-05648" ref-type="bibr">110</xref>]. This period depends on immune system status and the patient&#x02019;s age, being shorter in 70-year-old subjects compared with those younger [<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>,<xref rid="B110-ijerph-17-05648" ref-type="bibr">110</xref>]. In people with compromised immune systems and in elderly patients with underlying health problems, SARS-CoV-2 is able to infect the lower respiratory tract leading to severe pneumonia [<xref rid="B111-ijerph-17-05648" ref-type="bibr">111</xref>]. In 25&#x02013;30% of patients presenting acute lung injury, shock, ARDS and acute kidney injury, ICU admission was absolutely required [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>]. Recovery started within the 2nd or 3rd weeks with the median duration of hospitalization of 10 days. The virus appears to be more fatal in individuals with underlying co-morbidities (50&#x02013;75% of fatal cases) [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B111-ijerph-17-05648" ref-type="bibr">111</xref>]. Available dataset was obtained from Italian Istituto Superiore di Sanit&#x000e0; (ISS) on 34,026 patients dying in-hospitals (<xref ref-type="fig" rid="ijerph-17-05648-f007">Figure 7</xref>). The mean number of diseases was 3.3 (median 3, SD 1.9). Overall, 4.0% of the reported cases has no co-morbidities, 14.0% with a single comorbidity, 20.6% with 2 and 61.4% with 3 or more (<uri xlink:href="https://www.epicentro.iss.it/coronavirus/sars-cov-2">https://www.epicentro.iss.it/coronavirus/sars-cov-2</uri>).</p><p>SARS-CoV-2 infections revealed some unique clinical characteristics that include targeting the lower airway which is evident by symptoms of upper respiratory tract including rhinorrhoea, sneezing and sore throat [<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>]. Chest computed tomography (CT) scans revealed pneumonia in most SARS-CoV-2 infected patients and several cases showed an infiltrate in the upper lung lobe, which is related to increasing dyspnea with hypoxemia [<xref rid="B28-ijerph-17-05648" ref-type="bibr">28</xref>,<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>,<xref rid="B112-ijerph-17-05648" ref-type="bibr">112</xref>]. <xref rid="ijerph-17-05648-t004" ref-type="table">Table 4</xref> describes the full picture of COVID-19 clinical manifestation. Atypical symptoms include RNAemia, acute cardiac injury, ARDS and grand-glass opacities that lead to death [<xref rid="B113-ijerph-17-05648" ref-type="bibr">113</xref>]. It should be noted that COVID-19 manifestations such as fever, dyspnea, dry cough and bilateral ground-glass opacities in chest CT scans are similar to the previous <italic>Betacoronavirus</italic>-related diseases [<xref rid="B113-ijerph-17-05648" ref-type="bibr">113</xref>,<xref rid="B114-ijerph-17-05648" ref-type="bibr">114</xref>]. Although gastrointestinal symptoms such as diarrhea were reported in SARS-CoV-2 infected patients, the similar gastrointestinal distress occurred in only a small percentage of MERS-CoV or SARS-CoV patients (<xref ref-type="fig" rid="ijerph-17-05648-f006">Figure 6</xref>) [<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>]. It was shown that severe cases were characterized by an increased inflammation due to both systemic and localized immune response activation [<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>,<xref rid="B115-ijerph-17-05648" ref-type="bibr">115</xref>]. Higher leukocyte numbers, significantly high blood concentrations of cytokines and chemokines were noted in these cases [<xref rid="B28-ijerph-17-05648" ref-type="bibr">28</xref>,<xref rid="B78-ijerph-17-05648" ref-type="bibr">78</xref>]. Hence, it is now accepted that high levels of proinflammatory cytokines could worsen the prognosis [<xref rid="B28-ijerph-17-05648" ref-type="bibr">28</xref>,<xref rid="B113-ijerph-17-05648" ref-type="bibr">113</xref>].</p></sec><sec id="sec5-ijerph-17-05648"><title>5. Diagnosis</title><p>COVID-19 clinical evaluation is focused mainly on epidemiological data, clinical symptoms and clinical and laboratory tests. Although the scenario is continually changing, several approaches were selected as standard laboratory methods for COVID-19 diagnosis. Lab tests, differently from clinical-based analyses, immediately reveal SARS-CoV-2 infected patients. This was particularly important for diagnosis due to the difficulties in detecting specific clinical signs and symptoms in COVID-19 patients. Moreover, atypical manifestations revealed by pulmonary imaging [<xref rid="B116-ijerph-17-05648" ref-type="bibr">116</xref>] and the huge number of different clinical signs and symptoms forced the development of molecular-based laboratory tests [<xref rid="B117-ijerph-17-05648" ref-type="bibr">117</xref>,<xref rid="B118-ijerph-17-05648" ref-type="bibr">118</xref>]. Lastly, the analysis of personal history of each patient played a fundamental role in COVID-19 diagnosis and up to now is considered one of the key information for detecting infected patients also in the early phases of infection. Therefore, the epidemiological history together with clinical and laboratory tests are all required for the diagnosis of COVID-19. A detailed description focused on clinical diagnostic methods was reviewed by Taisheng Li [<xref rid="B119-ijerph-17-05648" ref-type="bibr">119</xref>]. Herein, we present an updated overview of the principal techniques used for COVID-19 diagnosis.</p><sec id="sec5dot1-ijerph-17-05648"><title>5.1. Nucleic Acid Detection Technology</title><p>High-throughput sequencing and real time quantitative polymerase chain reaction (RT-qPCR) are the best nucleic acid detection techniques for SARS-CoV-2. However, in clinical diagnosis, the application of high-throughput sequencing technology is limited due to high cost and its equipment dependency [<xref rid="B114-ijerph-17-05648" ref-type="bibr">114</xref>,<xref rid="B120-ijerph-17-05648" ref-type="bibr">120</xref>,<xref rid="B121-ijerph-17-05648" ref-type="bibr">121</xref>]. Moreover, to speed up the development of standardized analytic kits for diagnostic application, the quantification of viral load was not considered. Therefore, the RT-PCR method was chosen as the gold standard for the detection of SARS-CoV-2 infections from the commonly used samples such as naso- and oropharyngeal swabs [<xref rid="B106-ijerph-17-05648" ref-type="bibr">106</xref>,<xref rid="B107-ijerph-17-05648" ref-type="bibr">107</xref>,<xref rid="B121-ijerph-17-05648" ref-type="bibr">121</xref>,<xref rid="B122-ijerph-17-05648" ref-type="bibr">122</xref>]. This molecular method relies on the amplification of up to three SARS-CoV-2 specific targets including the RNA-dependent RNA polymerase (<italic>RdRp</italic>), <italic>E</italic> and <italic>N</italic> genes [<xref rid="B121-ijerph-17-05648" ref-type="bibr">121</xref>]. The WHO has released numerous RT-PCR protocols for the detection of SARS-CoV-2 RNA at <uri xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance</uri> (Accessed March 15, 2020). Three of those protocols are mentioned below. The US centers for disease control and prevention (CDC) developed an RT-PCR that includes three sets of oligonucleotide primers and probes recognizing three regions of the virus <italic>N</italic> gene (named N1, N2 and N3) and an additional primer/probe set to detect the human <italic>RNase P</italic> gene (RP) representing an internal control for RNA extraction and retro-transcription. Moreover, the positive control consisting in retro-transcribed viral RNA is also available at CDC. To report the positivity for SARS-CoV-2 two out of three N regions must be positive. The Chinese Center for Disease Control and Prevention (China CDC) recommends the use of specific primers and probes targeting the ORF1ab and <italic>N</italic> gene regions for SARS-CoV-2 detection by RT-PCR [<xref rid="B123-ijerph-17-05648" ref-type="bibr">123</xref>]. The positivity is confirmed when both targets are detected. Available online: <uri xlink:href="http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html">http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html</uri> (accessed on 21 January 2020).</p><p>Overall, the WHO summarized all the primer pairs and probes that can be used to detect SARS-CoV-2 in clinical specimens with the description of RT-PCR settings and the specificity. Apart from the possibility to perform the RT-PCR in house using the selected primer pairs and probes, several ready to use kits were developed for RT-PCR performing. One of the most used is the Allplex 2019-nCoV (Seegene, Seoul, South Korea) which includes three different viral targets and a positive control [<xref rid="B124-ijerph-17-05648" ref-type="bibr">124</xref>]. Another example is represented by the BGI&#x02019;s real-time fluorescent RT-PCR Kit for detecting SARS-CoV-2 that includes one SARS-CoV-2 specific target and an internal control of the reaction (BGI, Cambridge, MA, USA). Both companies declared a sensibility of 100&#x02013;150 viral copies per mL and a high specificity that excludes most respiratory tract viral and bacterial pathogens. The recommended samples for both in-house and ready-to-use RT-PCR kits include upper and lower respiratory specimens such as throat, nasal nasopharyngeal (NP) and/or oropharyngeal (OP) swabs, lower respiratory tract aspirates, sputum, bronchoalveolar lavage (BAL) fluid and nasopharyngeal wash/aspirate or nasal aspirate. It was observed that samples of the lower respiratory tract provide the higher viral loads [<xref rid="B74-ijerph-17-05648" ref-type="bibr">74</xref>]. On the other hand, it was shown that in the early stage of infection, the positive rate of RT-PCR was reported to be about 60% for throat swab samples [<xref rid="B125-ijerph-17-05648" ref-type="bibr">125</xref>]. Indeed, although being the gold standard, the RT-PCR presents some drawbacks. One of the most important is related to the sensibility because it was extensively reported that in the presence of low viral load this technique fails in detecting viral genome leading to false negative results [<xref rid="B126-ijerph-17-05648" ref-type="bibr">126</xref>]. Due to this problem, clinical governance as well as kit troubleshooting indicate to retest all the samples showing only single positive target along with patient resampling. To this respect, it should be underlined that operator skills or sampling sources can profoundly affect RT-PCR testing results [<xref rid="B22-ijerph-17-05648" ref-type="bibr">22</xref>]. Finally, during this pandemic several microbiologic labs worldwide are experiencing scarce availability of RNA extraction as well as ready-to-use RT-PCR kits increasing the timing of diagnosis confirmation through molecular approaches. Very recently, it was reported that the Allplex 2019-nCoV and the RealStar SARS-CoV-2 RT-PCR kits can amplify the target genes bypassing the RNA extraction step for a faster diagnosis [<xref rid="B127-ijerph-17-05648" ref-type="bibr">127</xref>].</p></sec><sec id="sec5dot2-ijerph-17-05648"><title>5.2. CT scans and Serology Methods</title><p>Although RT-PCR is specific for the diagnosis of COVID-19, its false-negative rate cannot be overlooked due to the severe consequences of missed diagnosis. Clinicians have demonstrated the usefulness of CT and chest radiography for the diagnosis of COVID-19 associated pneumonia [<xref rid="B128-ijerph-17-05648" ref-type="bibr">128</xref>]. Moreover, the ability of radiologists to diagnose COVID-19 pneumonia from chest CT evaluations has been reported to be very high [<xref rid="B129-ijerph-17-05648" ref-type="bibr">129</xref>]. Then a combination between RT-PCR and CT imaging represents the best approach for the correct COVID-19 diagnosis. In particular, for early detection and assessment of disease severity, the high-resolution CT (HRCT) of the chest is considered necessary [<xref rid="B130-ijerph-17-05648" ref-type="bibr">130</xref>,<xref rid="B131-ijerph-17-05648" ref-type="bibr">131</xref>]. One study analyzed the consistency and diagnostic value of RT-PCR test compared with chest CT in 1014 patients with suspected SARS-CoV-2 infection. Findings indicated that the chest CT sensitivity in suspected patients was 75% based on negative RT-PCR results and 97% based on positive RT-PCR results [<xref rid="B132-ijerph-17-05648" ref-type="bibr">132</xref>]. Moreover, Salehi et al. confirmed the higher sensibility of pulmonary imaging with respect to RT-PCR for COVID-19 diagnosis and showed a positive correlation between specific CT findings with the different stages of the disease and its severity [<xref rid="B116-ijerph-17-05648" ref-type="bibr">116</xref>]. The collection of numerous CT images has opened the possibility to build a database of pulmonary images from COVID-19 patients. Interestingly, the recent progress in integrating artificial intelligence (AI) with computer-aided design (CAD) software for diagnostic imaging revealed that AI could be used to support disease diagnosis [<xref rid="B133-ijerph-17-05648" ref-type="bibr">133</xref>,<xref rid="B134-ijerph-17-05648" ref-type="bibr">134</xref>]. Ito et al. reviewed the literature on the use of AI for lung diagnostic imaging of COVID-19 patients. Among the 15 selected studies, 11 used AI for CT and 4 used AI for chest radiography. The number of datasets ranged from 106 to 5941, with sensitivities ranging from 67&#x02013;100% and specificities ranging from 81&#x02013;100% for prediction of COVID-19 pneumonia. This study revealed the usefulness of AI approach to support the diagnosis of COVID-19, but also for future emerging diseases [<xref rid="B134-ijerph-17-05648" ref-type="bibr">134</xref>]. All the collected knowledge on lung lesions revealed some characteristic CT findings of COVID-19 pneumonia: the pulmonary ground-glass opacities in a peripheral distribution and the consolidation referring to an increase in pulmonary parenchymal density [<xref rid="B135-ijerph-17-05648" ref-type="bibr">135</xref>,<xref rid="B136-ijerph-17-05648" ref-type="bibr">136</xref>,<xref rid="B137-ijerph-17-05648" ref-type="bibr">137</xref>]. However, chest CT manifestations can vary in different patients and stages of infection, highlighting certain shortcomings of this approach. Apart from atypical manifestation that cannot be recognized by radiologists, several lung images are common in viral pneumonia leading to misdiagnosis [<xref rid="B138-ijerph-17-05648" ref-type="bibr">138</xref>]. Soon after the beginning of SARS-CoV-2 spreading, infected patients underwent antibody research for both basic research and clinical applications. One of the first studies reported the seroconversion of 100% of infected patients (<italic>n</italic> = 285) within 19 days after symptom onset. Seroconversion for IgM and IgG occurred simultaneously or sequentially and both immunoglobulins titers plateaued within 6 days after seroconversion. Importantly, the application of serology testing in surveillance in a cluster of 164 close contacts of COVID-19 patients identified 4.6% of positive patients showing negative RT-PCR results [<xref rid="B139-ijerph-17-05648" ref-type="bibr">139</xref>]. Hence, several studies underlined the recommended usage of serology to promote the detection of SARS-CoV-2 infections where NP swab specimens were improperly collected, molecular assays were unsatisfactorily carried out and for determining asymptomatic infections [<xref rid="B122-ijerph-17-05648" ref-type="bibr">122</xref>]. Based on these data, several companies developed kits for IgM/IgG testing showing a high detection rate of infected patients. Basically, there are two different testing methods: the rapid IgG-IgM test and the classical enzyme-linked immunosorbent assay (ELISA)-based test. The rapid test consists in a lateral flow qualitative immunoassay on a strip to detect the presence of both anti-SARS-CoV-2-IgM and anti-SARS-CoV-2-IgG in human specimens such as whole blood, serum and plasma. This IgG-and IgM-combined antibody test kit has a sensitivity of 88.66% and specificity of 90.63%. Results are obtained in 15 min leading to its useful application as point-of-care testing and in supporting RT-PCR-based diagnostic [<xref rid="B140-ijerph-17-05648" ref-type="bibr">140</xref>]. On the other hand, several ELISA-based kits are now commercially available, and their sensitivity and specificity were compared showing an overall high specificity, but a variable sensibility [<xref rid="B141-ijerph-17-05648" ref-type="bibr">141</xref>]. Differently from the rapid tests, the ELISA-based test should be performed on serum or plasma samples collected from venous sampling. Interestingly, the authors showed the neutralizing capacity of SARS-CoV-2 specific antibodies on Caco-2 cells directly incubating the sera from patients with the cell monolayers [<xref rid="B141-ijerph-17-05648" ref-type="bibr">141</xref>]. This assay is extremely important for the plasma-based therapies that are successfully used to treat seriously ill patients (see below). Finally, recently published papers described the seroconversion of COVID-19 patients including the evaluation of IgA that seems high in the early stages of infection (about 4 days&#x02019; post symptom development) [<xref rid="B142-ijerph-17-05648" ref-type="bibr">142</xref>,<xref rid="B143-ijerph-17-05648" ref-type="bibr">143</xref>]. Another interesting application of antibody detection is represented by the fluorescence immuno-chromatographic assay for the detection of SARS-CoV-2 nucleocapsid protein in human specimens such as NP swab [<xref rid="B144-ijerph-17-05648" ref-type="bibr">144</xref>]. It shows the fastness of rapid tests (results in 10 min), the possibility to use the same type of sample that is commonly used for RT-PCR-based diagnosis and high sensibility (detection of the nucleoprotein in all positive samples tested). Although these methods were suggested for COVID-19 diagnosis, the extent of antibodies production by infected patients is greatly variable. Moreover, the delay of antibodies production with respect to the onset of symptoms affects the use of this approach for diagnosis. Vice versa, it is reported that several governments, included Italy, are using serologic test for population screening to assess the proportion of people that have developed an immunological response against SARS-CoV-2 (<uri xlink:href="http://www.salute.gov.it/portale/nuovocoronavirus">http://www.salute.gov.it/portale/nuovocoronavirus</uri>). This screening will help also to detect asymptomatic and/or paucisymptomatic subjects.</p></sec></sec><sec id="sec6-ijerph-17-05648"><title>6. SARS-CoV-2 Therapeutics Strategies</title><p>The rapid spread of SARS-CoV-2 raises an urgent requirement for effective therapeutic strategies against COVID-19. Although many efforts have been intended to develop vaccines against HCoVs infections in recent years, there is no official and effective treatment against SARS-CoV-2. However, different considerable options have been applied for possible vaccine validity, efficacy and safety along with speeding up other ongoing searches to discover valuable modalities for dealing with the emerging COVID-19 [<xref rid="B12-ijerph-17-05648" ref-type="bibr">12</xref>,<xref rid="B145-ijerph-17-05648" ref-type="bibr">145</xref>,<xref rid="B146-ijerph-17-05648" ref-type="bibr">146</xref>,<xref rid="B147-ijerph-17-05648" ref-type="bibr">147</xref>,<xref rid="B148-ijerph-17-05648" ref-type="bibr">148</xref>].</p><p>Most of the drugs that are being used to cope with COVID-19 epidemic are directed towards specific viral molecular targets and biologic processes through which the virus spreads damaging the host. In line, all available experimental therapies for COVID-19 management are based on previous experiences in treating SARS-CoV and MERS-CoV infections, such as inhibitors of SARS-CoV-2 fusion/entry/replication, anti-viral agents against main viral proteases, regulators of SARS-CoV-2 induced host inflammatory response and direct administration of human monoclonal antibodies (mAbs) (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>) [<xref rid="B149-ijerph-17-05648" ref-type="bibr">149</xref>]. Apart from all these possible therapeutic approaches, it has been reported that the Chinese medicine products, as Lianhuaqingwen and ShuFeng JieDu capsules may be helpful for SARS-CoV-2 treatment [<xref rid="B12-ijerph-17-05648" ref-type="bibr">12</xref>,<xref rid="B150-ijerph-17-05648" ref-type="bibr">150</xref>]. Indeed, this product is mainly used to treat upper respiratory tract infections such as the flu, swelling and pain in the throat, mumps and strep throat [<xref rid="B151-ijerph-17-05648" ref-type="bibr">151</xref>,<xref rid="B152-ijerph-17-05648" ref-type="bibr">152</xref>]. Moreover, four COVID-19 cases have been described to gain improvement after taking combined Chinese and Western medicine [<xref rid="B153-ijerph-17-05648" ref-type="bibr">153</xref>]. Notably, encouraging progress in deciphering SARS-CoV-2 genome will lead to new potential therapeutic targets. Likewise, more prospective, rigorous population studies are urgently required to confirm the therapeutic effect as well as the safety of new potential therapeutic strategies in order to further implement robust preventive and control measures against SARS-CoV-2 spread.</p><sec id="sec6dot1-ijerph-17-05648"><title>6.1. Inhibitors of SARS-CoV-2 Fusion/Entry</title><p>As outlined above, multiple strategies are aimed at developing CoVs vaccines, most of which are headed for the surface-exposed spike (S protein) glycoprotein as the major virus&#x02013;host cell membrane interactor. To this aim, vaccines under study are based on full-length S protein, S1-RBD, expression of virus-like particles (VLP), DNA or viral vectors [<xref rid="B42-ijerph-17-05648" ref-type="bibr">42</xref>,<xref rid="B154-ijerph-17-05648" ref-type="bibr">154</xref>,<xref rid="B155-ijerph-17-05648" ref-type="bibr">155</xref>,<xref rid="B156-ijerph-17-05648" ref-type="bibr">156</xref>,<xref rid="B157-ijerph-17-05648" ref-type="bibr">157</xref>,<xref rid="B158-ijerph-17-05648" ref-type="bibr">158</xref>]. As outlined above, the S1 includes the RBD that interacts with its host cell receptor, ACE2, whereas the S2 mediates fusion between the virus and host cell membranes promoting the entry and subsequent replication of the viral RNA into the cytoplasm [<xref rid="B158-ijerph-17-05648" ref-type="bibr">158</xref>]. The ACE2 receptor, as a specific biologic target for vaccine development, is under study in a controlled pilot clinical trial to investigate the effect of recombinant human ACE2 (rhACE2; GSK2586881) in patients with severe COVID-19 (NCT04287686) (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>I) [<xref rid="B159-ijerph-17-05648" ref-type="bibr">159</xref>,<xref rid="B160-ijerph-17-05648" ref-type="bibr">160</xref>]. Vice versa, both recombinant proteins containing RBD and the recombinant vectors encoding RBD can be used to generate the effective SARS-CoV vaccines given the capability of this domain to induce neutralizing antibody [<xref rid="B156-ijerph-17-05648" ref-type="bibr">156</xref>]. Indeed, the first available SARS-CoV-specific human monoclonal antibody with neutralizing activity against SARS-CoV, named CR3022, was found to bind potently to SARS-CoV-2 RBD, in agreement with the high homology shared by this domain with SARS-CoV homolog [<xref rid="B161-ijerph-17-05648" ref-type="bibr">161</xref>]. However, it must be taken into account that more than 85% of the RBD antibody epitopes in SARS-CoV-2 show implicit noticeable changes, indicating the necessity to develop more specific monoclonal antibodies for SARS-CoV-2 [<xref rid="B162-ijerph-17-05648" ref-type="bibr">162</xref>].</p><p>Angiotensin receptor blockers (ARBs), such as losartan, valsartan, telmisartan, usually assumed for treating high blood pressure, heart and kidney failure in people with diabetes, have been recently proposed as a novel therapeutic approach to block SARS-CoV-2 RBD binding to ACE2- expressing cells binding, similarly to ACE inhibitors [<xref rid="B163-ijerph-17-05648" ref-type="bibr">163</xref>].</p><p>Additional targetable epitopes that should be considered are the heptad repeat 1 (HR1) and heptad repeat 2 (HR2) in SARS-CoV-2 S protein. In fact, the HR2-derived peptides (HR2P) and EK1 (a modified OC43-HR2P peptide), exhibit effective fusion inhibitory activity towards SARS-CoV-2, suggesting a promising strategy in treating SARS-CoV-2 infection, although further studies are required to strengthen these hypotheses (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>I) [<xref rid="B164-ijerph-17-05648" ref-type="bibr">164</xref>,<xref rid="B165-ijerph-17-05648" ref-type="bibr">165</xref>].</p><p>Lately, immuno-informatics have been employed to identify significant cytotoxic T lymphocyte (CTL) and B-cell epitopes in SARS-CoV-2 S protein, such as the nucleocapsid (N) protein as well as the potential B cell epitopes of the E protein of MERS-CoV as likely immunoprotective targets [<xref rid="B166-ijerph-17-05648" ref-type="bibr">166</xref>,<xref rid="B167-ijerph-17-05648" ref-type="bibr">167</xref>].</p><p>Reverse genetic strategies have been successfully used in live-attenuated vaccines to inactivate the exonuclease effects of non-structural protein 14 (nsp14) or to wipe out the envelope protein in SARS [<xref rid="B154-ijerph-17-05648" ref-type="bibr">154</xref>]. A recent study also revealed that the invasion process requires the priming of the S protein which is facilitated by the host cell produced serine protease TMPRSS211. The clinically demonstrated serine protease TMPRSS2 inhibitor Camostat mesylate, which partially blocks SARS-CoV-2 entry into host cells, was shown to be a good target to significantly reduce pulmonary infection in COVID-19 affected individuals (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>I) [<xref rid="B168-ijerph-17-05648" ref-type="bibr">168</xref>] Moreover, it has been suggested that coronavirus entry also involves pH and receptor-dependent endocytosis [<xref rid="B169-ijerph-17-05648" ref-type="bibr">169</xref>,<xref rid="B170-ijerph-17-05648" ref-type="bibr">170</xref>]; thus, targeting endocytosis may be another assessable option for fighting SARS-CoV-2 (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>I). In this view, throughout AI technology, a group of approved drugs, such as the Janus kinase (JAK) inhibitor baricitinib [<xref rid="B171-ijerph-17-05648" ref-type="bibr">171</xref>] targeting the AP-2-associated protein kinase 1 (AAK1) regulating clathrin-mediated endocytosis, has been developed (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>I) [<xref rid="B172-ijerph-17-05648" ref-type="bibr">172</xref>]. Furthermore, other drugs such as arbidol (ChiCTR2000029621), a haemagglutinin inhibitor and chloroquine phosphate, a traditional antimalarial drug, have been added to the National Health Commission of the People&#x02019;s Republic of China (NHC) guidelines for COVID-19 treatment (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>I) (<uri xlink:href="http://www.nhc.gov.cn">http://www.nhc.gov.cn</uri>). In particular, in vitro studies have demonstrated that chloroquine as well as hydroxychloroquine could impair the endosome-mediated viral entry or later stages of viral replication [<xref rid="B173-ijerph-17-05648" ref-type="bibr">173</xref>]. Combination of hydroxychloroquine and azithromycin has also been suggested as a valid approach since it showed more rapid resolution of infection than hydroxychloroquine alone [<xref rid="B174-ijerph-17-05648" ref-type="bibr">174</xref>]; however, the combined use of azithromycin and hydroxychloroquine seems to be associated with at increased risk of arrhythmias. Available online: <uri xlink:href="https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19">https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19</uri> (accessed on 29 March 2020).</p></sec><sec id="sec6dot2-ijerph-17-05648"><title>6.2. Inhibitors of SARS-CoV-2 Main Enzymes</title><p>To date, several attempts have also been made in targeting viral main enzymes; in fact, many inhibitory drugs targeting the coronavirus main proteinase 3C-like protease (3CLpro) have been validated in clinical trials (e.g., Lopinavir/Ritonavir; ChiCTR2000029387, ChiCTR2000029468, ChiCTR2000029539) (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>II) [<xref rid="B175-ijerph-17-05648" ref-type="bibr">175</xref>]. Moreover, four additional molecules including prulifloxacin, tegobuvir, bictegravir and nelfinavir, detected by high-throughput screening, showed reasonable binding conformations with the viral main protease [<xref rid="B176-ijerph-17-05648" ref-type="bibr">176</xref>]. Moreover, a recent study by performing a virtual screening using a three-dimensional model of the SARS-CoV-2 3C-like protease (3CL), identified 16 biologic candidates that deserve further consideration. Among these, the antivirals Ledipasvir or Velpatasvir proved to be particularly attracting as therapeutics to combat the new coronavirus showing optimal anti-viral activity and minimal side effects, such as fatigue and headache; also, Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) are promising antivirals, not only for their effective and synergic inhibitory activities against two viral enzymes, but also for their minimized possibilities to develop resistance [<xref rid="B177-ijerph-17-05648" ref-type="bibr">177</xref>].</p></sec><sec id="sec6dot3-ijerph-17-05648"><title>6.3. Inhibitors of SARS-CoV-2 Replication</title><p>A certain number of clinical trials on antiviral drugs aimed to arrest SARS-CoV-2 replication are currently in progress, such as Remdesivir (NCT04252664, NCT04257656) Favipiravir (ChiCTR2000029600, ChiCTR2000029544) and ASC09 (ChiCTR2000029603) (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>III). Among these, Remdesivir was recently approved for medical use in America and European Union and seems to be the most promising antiviral for fighting SARS-CoV-2 [<xref rid="B178-ijerph-17-05648" ref-type="bibr">178</xref>] (<uri xlink:href="http://www.who.int">http://www.who.int</uri>), as in vitro studies demonstrated that this molecule, a mono-phosphoramidate prodrug of an adenosine, effectively inhibited SARS-CoV-2 RNA synthesis [<xref rid="B179-ijerph-17-05648" ref-type="bibr">179</xref>]. Targeting the SARS-CoV-2 RNA genome could, therefore, be another potential strategy. In fact, a CRISPR/Cas13d technology, which is an RNA-guided RNA-targeting CRISPR system, has been employed to specifically chew up SARS-CoV-2 RNA genome. In this system, a Cas13d protein and guide RNAs-containing spacer sequences are used to specifically complement the virus RNA genome (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>IV). Furthermore, RNA genome can be packaged into one adeno-associated virus (AAV) vector, making the CRISPR/Cas13d system more efficient for virus elimination and resistance prevention, taking into account that AAV has serotypes highly specific to the lung, the main organ infected by SARS-CoV-2 [<xref rid="B180-ijerph-17-05648" ref-type="bibr">180</xref>].</p></sec><sec id="sec6dot4-ijerph-17-05648"><title>6.4. Modulators of SARS-CoV-2 Induced Inflammatory Response</title><p>In addition to antiviral therapy, a new treatment strategy having a significant impact on clinical outcomes is utmost required. Immunomodulatory therapy to downregulate the cytokine storm may provide great benefit to the treatment of COVID-19. Recently, researchers focused on targeting specific molecular markers involved in inflammatory cytokines-receptors interactions, their correlation in health and disease and drugs in use that can activate or block their actions. A higher concentration of cytokines has been found in the plasma from COVID-19 patients in ICU compared with the ones from non-ICU COVID-19 patients, suggesting that the cytokine storm could be linked to the severity of the disease [<xref rid="B113-ijerph-17-05648" ref-type="bibr">113</xref>]. Corticosteroids are among the most commonly used drugs for immunomodulatory therapy of infectious diseases. However, the use of corticosteroids in the treatment of COVID-19 can cause host immune suppression and delay of viral clearance. A recent study on 201 patients with ARDS showed that treatment with methylprednisolone decreased the risk of death (hazard ratio 0.38, 95% confidence interval 0.20&#x02013;0.72). These findings indicate that using corticosteroids does not influence viral clearance time, length of hospital stays or duration of symptoms in patients with mild COVID-19 [<xref rid="B181-ijerph-17-05648" ref-type="bibr">181</xref>]. Thus, the use of corticosteroids is considered beneficial in severe cases of COVID-19 (especially in patients with ARDS), but not in mild cases. Accordingly, a recent retrospective study showed the potential benefits from low-dose corticosteroids treatment in a subset of critically SARS-CoV-2 patients [<xref rid="B182-ijerph-17-05648" ref-type="bibr">182</xref>]; these data are in contrast with NHC guidelines that highlight that systematic use of corticosteroids is not recommended for these cases, due to their immunosuppressive effects. However, administration of corticosteroids has been indicated for specific reasons such as exacerbation of asthma or chronic obstructive pulmonary disease (COPD), septic shock or severe acute respiratory distress syndrome (ARDS). Further studies are required to find out how and when it is appropriate the use of corticosteroids for COVID-19, as there are no available data on the benefits of corticosteroid treatment in SARS-CoV or MERS infection [<xref rid="B183-ijerph-17-05648" ref-type="bibr">183</xref>].</p><p>Apart from corticosteroids, IL-6 pathway inhibitors such as sarilumab, siltuximab and tocilizumab have been proposed as experimental approach considering the increased IL-6 levels that have been observed in patients with severe COVID-19 [<xref rid="B184-ijerph-17-05648" ref-type="bibr">184</xref>]. Tocilizumab is a recombinant, humanized monoclonal antibody commonly used for treating patients with rheumatoid arthritis, lupus and psoriasis that binds to IL-6 receptors blocking FcR activation; in COVID-19 patients, Tocilizumab could reduce SARS-CoV-2-induced inflammatory responses [<xref rid="B185-ijerph-17-05648" ref-type="bibr">185</xref>]. Accordingly, several case reports have referred positive outcomes regarding Tocilizumab [<xref rid="B113-ijerph-17-05648" ref-type="bibr">113</xref>,<xref rid="B186-ijerph-17-05648" ref-type="bibr">186</xref>,<xref rid="B187-ijerph-17-05648" ref-type="bibr">187</xref>,<xref rid="B188-ijerph-17-05648" ref-type="bibr">188</xref>,<xref rid="B189-ijerph-17-05648" ref-type="bibr">189</xref>,<xref rid="B190-ijerph-17-05648" ref-type="bibr">190</xref>], but clinical impact of Tocilizumab on COVID-19 patients as an approved clinical approach has not been evaluated yet. In line, to further investigate the efficacy and safety of Tocilizumab in patients with COVID-19, a controlled clinical trial is now under way (ChiCTR2000029765) (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>V). Overall, the combination of an immunomodulatory agent to reduce the cytokine storm with an antiviral agent may give physicians more time to provide supportive treatment for patients with COVID-19.</p></sec><sec id="sec6dot5-ijerph-17-05648"><title>6.5. Passive Immunization</title><p>At the time of writing this review, due to the lack of a specific available therapy, plasma from convalescent patients containing specific antibodies has been proposed as a principal treatment [<xref rid="B190-ijerph-17-05648" ref-type="bibr">190</xref>,<xref rid="B191-ijerph-17-05648" ref-type="bibr">191</xref>], for patients in rapid disease progression, severe or critical conditions (<xref ref-type="fig" rid="ijerph-17-05648-f008">Figure 8</xref>VI). In a recent retrospective study, one dose (200 mL) of convalescent plasma (CP) collected from 10 severe adult cases has been reported to be tolerated; thus, increasing or maintaining high level of neutralizing antibodies broke down the viral load in seven days, improve clinical symptoms and paraclinical criteria within three days and lung lesions were found to be differently absorbed on radiological examination within seven days [<xref rid="B192-ijerph-17-05648" ref-type="bibr">192</xref>]. Therefore, being CP a promising rescue option for severe COVID-19, several clinical trials (ChiCTR2000030010, ChiCTR2000030179, and ChiCTR2000030381) are in progress to investigate the efficacy and safeness of CP direct infusion in COVID-19 patients [<xref rid="B191-ijerph-17-05648" ref-type="bibr">191</xref>]. In addition, combined therapy with mAbs and Remdesivir seems to be an ideal therapeutic option for COVID-19 [<xref rid="B193-ijerph-17-05648" ref-type="bibr">193</xref>]. Pharmaceuticals companies are now focused on searching for specific and effective mAbs against COVID-19. Taking into account that technologies capable of making fully human antibodies such as human single-chain antibody variable fragments (Hu-scFvs) or humanized-nanobodies (single-domain antibodies, sdAb) able to overpass virus-infected cell membranes (trans bodies) and to interact or interpose with biologic processes required for virus replication are already available [<xref rid="B194-ijerph-17-05648" ref-type="bibr">194</xref>].</p></sec><sec id="sec6dot6-ijerph-17-05648"><title>6.6. Cell-Based Therapies</title><p>A large number of clinical trials regarding cell-based therapies have been started in China during COVID-19 outbreak. Among these, mesenchymal stromal cells (MSCs)-based therapy displayed strong safety profile and possible efficacy in patients with ARDS, according to COVID-19-related clinical studies listed on the WHO&#x02019;s International Clinical Trials Registry Platform (WHO ICTRP) and National Institutes of Health&#x02019;s clinical trials.gov databases [<xref rid="B195-ijerph-17-05648" ref-type="bibr">195</xref>]. Nevertheless, further investigations are required to better understand if these therapies could be effective in treating respiratory virus-induced complications. MSCs have been largely employed in basic research and clinical trials [<xref rid="B196-ijerph-17-05648" ref-type="bibr">196</xref>,<xref rid="B197-ijerph-17-05648" ref-type="bibr">197</xref>,<xref rid="B198-ijerph-17-05648" ref-type="bibr">198</xref>], and their safeness and effectiveness have been extensively documented especially in immune-mediated inflammatory disorders, such as graft-versus-host disease (GVHD) [<xref rid="B199-ijerph-17-05648" ref-type="bibr">199</xref>] and systemic lupus erythematosus (SLE) [<xref rid="B200-ijerph-17-05648" ref-type="bibr">200</xref>]. MSCs immunomodulatory and differentiation abilities [<xref rid="B201-ijerph-17-05648" ref-type="bibr">201</xref>] as well as their competency to produce several cytokine types or to directly interact with immune cells have been already described [<xref rid="B202-ijerph-17-05648" ref-type="bibr">202</xref>]. Indeed, they are activated by pathogen-associated molecules (PAMPs) such as single or double-stranded RNAs [<xref rid="B203-ijerph-17-05648" ref-type="bibr">203</xref>,<xref rid="B204-ijerph-17-05648" ref-type="bibr">204</xref>], priming the immune response during infections. Two clinical investigations of systemic MSC administration in patients with either COVID-19 or avian influenza A (H7N9) have been recently published [<xref rid="B205-ijerph-17-05648" ref-type="bibr">205</xref>,<xref rid="B206-ijerph-17-05648" ref-type="bibr">206</xref>]. The first one, a single-center MSC transplantation pilot study, was aimed at exploring MSCs therapeutic potentiality in patients with COVID-19 pneumonia and conducted at the You&#x02019;an Hospital in Beijing, China, from 23 Jan 2020 to 16 Feb 2020 (ChiCTR2000029990). Seven patients with COVID-19 pneumonia, SARS-CoV-2 RNA positive, with different degrees of severity, including one critically ill requiring ICU care were enrolled and monitored for 14 days after MSC injection. A significant improvement of pulmonary function and symptoms were observed two days after MSC transplantation characterized by an increase of peripheral lymphocytes and of the anti-inflammatory IL-10 levels and a decrease of the C-reactive protein and TNF-&#x003b1; amounts [<xref rid="B205-ijerph-17-05648" ref-type="bibr">205</xref>]. Moreover, an increment of the CD14 + CD11c + CD11b<sup>mid</sup> regulatory dendritic cell (DC) population and a decrease of cytokine-secreting immune cells such as CXCR3 + CD4 + T cells, CXCR3 + CD8 + T cells, and CXCR3 + NK were detected within 3&#x02013;6 days in the treated patients compared to the placebo control group [<xref rid="B205-ijerph-17-05648" ref-type="bibr">205</xref>]. MSCs play a role in attenuating cytokine storm, most importantly, because these cells do not express ACE2 and TMPRSS2 viral receptors are insusceptible of SARS-CoV-2 infection. These observations are in agreement with the knowledge that MSCs induce the maturation of dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population [<xref rid="B207-ijerph-17-05648" ref-type="bibr">207</xref>], shifting the Th1/Th2 balance towards Th2. Thus, from these preliminary results, it seems evident that MSCs intravenous transplantation could represent a secure and effective treatment in patients with COVID-19 pneumonia, especially those critical. Indeed, it inhibits the over activation of the immune system and promotes endogenous repair by preventing pulmonary fibrosis and improving both pulmonary microenvironment and lung function [<xref rid="B205-ijerph-17-05648" ref-type="bibr">205</xref>].</p></sec><sec id="sec6dot7-ijerph-17-05648"><title>6.7. Vaccines</title><p>More than 15 potential vaccine candidates for COVID-19 are under development around the world, including inactivated, recombinant subunits, nucleic-acid-based, adenoviral vector, and recombinant influenza viral vector vaccines [<xref rid="B208-ijerph-17-05648" ref-type="bibr">208</xref>]. Moreover, taking into consideration the strong homologies existing among the various coronavirus strains, it was thought that vaccines acting on other coronaviruses, such the avian live IBV vaccine (strain H) directed towards the chicken CoV IBV, could be a valuable alternative therapeutic strategy [<xref rid="B209-ijerph-17-05648" ref-type="bibr">209</xref>].</p><p>The Coalition for Epidemic Preparedness Innovations (CEPI) recently announced that three programs aimed to develop COVID-19 vaccines, by utilizing established vaccine platforms, have started [<xref rid="B210-ijerph-17-05648" ref-type="bibr">210</xref>]. In addition, CEPI already financed the company Moderna, Inc. to compare mRNA therapeutics and vaccines, allowing the release of the first batch of mRNA-1273 in February 2020, which is an mRNA vaccine against SARS-CoV-2 ready for phase I study in the United States. Available online: <uri xlink:href="https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273">https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273</uri> (accessed on 24 February 2020).</p><p>More recently, scientists from the University of Pittsburgh have announced a potential vaccine against SARS-CoV-2, delivered throughout a fingertip-sized patch, capable of producing SARS-CoV-2 specific IgG antibodies, sufficient for virus neutralization in mice. This vaccine, called PittCoVacc (acronym of Pittsburgh coronavirus vaccine), is a trimeric recombinant SARS-CoV-2-S1 subunit vaccine delivered intracutaneously by microneedle arrays (MNAs) [<xref rid="B211-ijerph-17-05648" ref-type="bibr">211</xref>]. Delivering vaccine components to a defined skin microenvironment improves safety by reducing systemic exposure, allowing to reach high vaccine concentrations with a relatively low dose of antigen [<xref rid="B212-ijerph-17-05648" ref-type="bibr">212</xref>,<xref rid="B213-ijerph-17-05648" ref-type="bibr">213</xref>]. Furthermore, the skin delivery strategy promotes strong and long-lasting antigen-specific antibody responses due to both the high immunogenicity [<xref rid="B214-ijerph-17-05648" ref-type="bibr">214</xref>,<xref rid="B215-ijerph-17-05648" ref-type="bibr">215</xref>,<xref rid="B216-ijerph-17-05648" ref-type="bibr">216</xref>,<xref rid="B217-ijerph-17-05648" ref-type="bibr">217</xref>,<xref rid="B218-ijerph-17-05648" ref-type="bibr">218</xref>] and the redundant immunoregulatory circuits of the skin [<xref rid="B217-ijerph-17-05648" ref-type="bibr">217</xref>,<xref rid="B219-ijerph-17-05648" ref-type="bibr">219</xref>,<xref rid="B220-ijerph-17-05648" ref-type="bibr">220</xref>]. Given the urgent need for COVID-19 vaccines, MNAs strategy seems to be a promising immunization approach against coronavirus infection including SARS, MERS and other emerging infectious diseases.</p><p>On April 24, the Oxford ChAdOx1 nCov-19 vaccine was the first in Europe to start human trial stage, with 1110 healthy volunteers enrolled for the tests. Oxford scientists have already employed ChAdOx1 in the past to dispense vaccines against Ebola, Chikungunya, Rift Valley fever and, above all, MERS. ChAdOx1, a chimpanzee-derived adenovirus vector, has been employed to deliver the full-length MERS spike gene and shown to induce large amounts of neutralizing antibodies against MERS in a mouse model [<xref rid="B221-ijerph-17-05648" ref-type="bibr">221</xref>,<xref rid="B222-ijerph-17-05648" ref-type="bibr">222</xref>]. Therefore, the modified ChAdOx1 vaccine, carrying the SARS-CoV-2 spike gene is under human trial stage. On April 30, the University of Oxford has announced a collaboration with the UK-based global biopharmaceutical company AstraZeneca for further development, large-scale production and potential delivery of the COVID-19 vaccine candidate. Available online: <uri xlink:href="https://www.ovg.ox.ac.uk/news/landmark-partnership-announced-for-development-of-covid-19-vaccine">https://www.ovg.ox.ac.uk/news/landmark-partnership-announced-for-development-of-covid-19-vaccine</uri> (accessed on 30 April 2020). Since ChAdOx technology is already available and formerly tested in humans for other vaccines, Phase III will consist in administering vaccine to volunteers following them into their regular environments to ensure that these subjects actually become immune to the disease up to three years. If trials succeed, Oxford researchers have proposed to complete testing throughout ring vaccination, namely delivering vaccine to members of the first circle of contacts of COVID-19 positive people and then to evaluate if the virus spreads to the second circle, as was previously done during the 2018 Ebola epidemic in the Democratic Republic of the Congo.</p><p>Overall, a joint effort headed to apply both already consolidate and innovative approaches, such as AI to facilitate drug discovery, will be required to develop a broad-spectrum antiviral drugs and vaccines towards existing and potential future coronavirus infections to prevent another highly pathogenic virus epidemic. Moreover, continuous collaboration in basic and clinical studies will improve the discovery of new antiviral drugs with therapeutic potentials, decrease the time for drug release on the market and make them affordable for all countries. Furthermore, vaccine delivery strategies and cell-based therapies benefit from the significant progresses made by recombinant DNA technologies combined with emerging biotechnology and bioengineering methodologies. Thus, these approaches can speed up the development and set up of new vaccines and clinical therapies to fight against novel pathogens to protect public health all over the world.</p></sec></sec><sec sec-type="conclusions" id="sec7-ijerph-17-05648"><title>7. Conclusions</title><p>This study represents a holistic picture of the current investigations in response to the outbreak of COVID-19. The current pandemic is obviously an international public health problem and it remains a challenging task to fight the SARS-CoV-2 of unknown origin and mysterious biologic features. Lesson from the previous two pandemics, MERS and SARS outbreaks, provide valuable insights about how to manage the current pandemic and provide a reference for future studies to combat disease progression. Despite SARS-CoV-2 rapid transmission, the scale up country readiness, speedy response teams and the capacity of all laboratories are reducing the spread of the virus as well as its mortality rate. As the pandemic is still ongoing and expanding, further studies on all aspects of the disease are needed to better understand the infection, beneficial treatments and development of vaccines. Nevertheless, this pandemic, together with the previous ones, have taught us in the harshest possible way that the entire scientific community must be vigilant and ready to advice appropriate containment and screening measures to avoid the spread of any future emerging pathogen.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to acknowledge Majidi Nezhad for providing the meteorological data and climate analyses and Gaia Scoarughi and Adeleh Salehi for drawing figures.</p></ack><notes><title>Author Contributions</title><p>H.H. and M.S. conceived, planned the project and organized the manuscript; H.H., F.P.S., H.S., A.D.L. and M.S. performed a literature search and prepared the draft of the manuscript; H.H., F.P.S., H.S., A.D.L., L.M., R.R., D.S., C.A. and M.S. participated in data curation and writing&#x02014;revising the manuscript. H.H., L.M., R.R., D.S., C.A. and M.S. discussed the conception of the review and contributed to the final manuscript preparation. H.H., D.S., C.A. and M.S. supervised the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript: 16 nonstructural polyproteins (nsps 1&#x02013;16); 2019 novel coronavirus (2019-nCoV); 3-chymotrypsin-like protease (3CLpro); 3C-like protease (3CL); Acute respiratory distress syndrome (ARDS); adeno-associated virus (AAV); angiotensin receptor blockers (ARBs); angiotensin-converting enzyme 2 (ACE2); AP-2-associated protein kinase 1 (AAK1); artificial intelligence (AI); avian infectious bronchitis virus (IBV); basic reproduction number (R0); blood oxygen saturation (SpO2); bronchoalveolar lavage (BAL); centers for disease control and prevention (CDC); Chinese Center for Disease Control and Prevention (China CDC); chronic obstructive pulmonary disease (COPD); Coalition for Epidemic Preparedness Innovations (CEPI); computed tomography (CT); computer-aided design (CAD); convalescent plasma (CP); coronavirus (CoV); cytotoxic T lymphocyte (CTL); dendritic cell (DC); dipeptidyl peptidase 4 (DPP4, also known as CD26); envelope glycoprotein (E); enzyme-linked immunosorbent assay (ELISA); European Center for Medium-Range Weather Forecasts (ECMWF); European cities (ECs); feline infectious peritonitis (FIP); graft versus-host disease (GVHD); hemagglutinin-esterase glycoprotein (HE); heptad repeat 1 (HR1) and heptad repeat 2 (HR2); high-resolution CT (HRCT); HR2-derived peptides (HR2P); EK1 (a modified OC43-HR2P peptide); human coronaviruses (HCoVs); human CoVs (HCoVs); human single-chain antibody variable fragments (Hu-scFvs); humanized-nanobodies (single-domain antibodies, sdAb); intensive care unit (ICU); Istituto Superiore di Sanit&#x000e0; (ISS); Janus kinase (JAK); membrane glycoprotein (M); mesenchymal stromal cells (MSCs); microneedle arrays (MNAs); Middle East Respiratory syndrome coronavirus (MERS-CoV); monoclonal antibodies (mAbs); naso-pharyngeal (NP); National Health Commission of the People&#x02019;s Republic of China (NHC); nonstructural protein 14 (nsp14); Northern Hemisphere (NH); nucleocapsid phosphoprotein (N); open reading frames (ORFs); oro-pharyngeal (OP); papain-like protease (PLpro); partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2); pathogen-associated molecules (PAMPs); Pittsburgh coronavirus vaccine (PittCoVacc); polypeptides (pps); porcine epidemic diarrhea virus (PEDV); real time quantitative polymerase chain reaction (RT-qPCR); receptor-binding domain (RBD); recombinant human ACE2 (rhACE2); replication&#x02013;transcription complex (RTC); RNA-dependent RNA polymerase (<italic>RdRp</italic>); <italic>RNase P</italic> gene (RP); severe acute respiratory syndrome coronavirus (SARS-CoV); single-stranded positive-sense RNA (+ssRNA); Southern Hemisphere (SH); spike glycoprotein (S); subgenomic RNAs (sgRNAs); swine acute diarrhea syndrome coronavirus (SADS-CoV); swine enteric <italic>Alphacoronaviruses</italic> (SeACoVs); systemic lupus erythematosus (SLE); transmissible gastroenteritis virus (TGEV); virus-like particles (VLP); WHO&#x02019;s International Clinical Trials Registry Platform (WHO ICTRP); World Health Organization (WHO).</p></glossary><ref-list><title>References</title><ref id="B1-ijerph-17-05648"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Woo</surname><given-names>P.C.</given-names></name></person-group><article-title>The emerging novel Middle East respiratory syndrome coronavirus: The &#x0201c;knowns&#x0201d; and &#x0201c;unknowns&#x0201d;</article-title><source>J. Formos. Med. Assoc.</source><year>2013</year><volume>112</volume><fpage>372</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2013.05.010</pub-id><?supplied-pmid 23883791?><pub-id pub-id-type="pmid">23883791</pub-id></element-citation></ref><ref id="B2-ijerph-17-05648"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Coronaviruses&#x02014;Drug discovery and therapeutic options</article-title><source>Nat. Rev. Drug Discov.</source><year>2016</year><volume>15</volume><fpage>327</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.37</pub-id><?supplied-pmid 26868298?><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="B3-ijerph-17-05648"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: Genome structure, replication, and pathogenesis</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><?supplied-pmid 31967327?><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="B4-ijerph-17-05648"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>T.S.</given-names></name><name><surname>Liu</surname><given-names>D.X.</given-names></name></person-group><article-title>Human Coronavirus: Host-Pathogen Interaction</article-title><source>Annu. Rev. Microbiol.</source><year>2019</year><volume>73</volume><fpage>529</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id><pub-id pub-id-type="pmid">31226023</pub-id></element-citation></ref><ref id="B5-ijerph-17-05648"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>S.A.</given-names></name><name><surname>Sheikh</surname><given-names>F.N.</given-names></name><name><surname>Jamal</surname><given-names>S.</given-names></name><name><surname>Ezeh</surname><given-names>J.K.</given-names></name><name><surname>Akhtar</surname><given-names>A.</given-names></name></person-group><article-title>Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment</article-title><source>Cureus</source><year>2020</year><volume>12</volume><fpage>e7355</fpage><pub-id pub-id-type="doi">10.7759/cureus.7355</pub-id><pub-id pub-id-type="pmid">32328367</pub-id></element-citation></ref><ref id="B6-ijerph-17-05648"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyrrell</surname><given-names>D.A.</given-names></name><name><surname>Bynoe</surname><given-names>M.L.</given-names></name></person-group><article-title>Cultivation of a novel type of common-cold virus in organ cultures</article-title><source>Br. Med. J.</source><year>1965</year><volume>1</volume><fpage>1467</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1136/bmj.1.5448.1467</pub-id><pub-id pub-id-type="pmid">14288084</pub-id></element-citation></ref><ref id="B7-ijerph-17-05648"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Coronavirus genomics and bioinformatics analysis</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>1804</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.3390/v2081803</pub-id><pub-id pub-id-type="pmid">21994708</pub-id></element-citation></ref><ref id="B8-ijerph-17-05648"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>F.W.</given-names></name></person-group><article-title>Evaluation of risks and benefits associated with vaccination against coronavirus infections in cats</article-title><source>Adv. Vet. Med.</source><year>1999</year><volume>41</volume><fpage>347</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/s0065-3519(99)80026-3</pub-id><pub-id pub-id-type="pmid">9890027</pub-id></element-citation></ref><ref id="B9-ijerph-17-05648"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><name><surname>Preiser</surname><given-names>W.</given-names></name><name><surname>van der Werf</surname><given-names>S.</given-names></name><name><surname>Brodt</surname><given-names>H.R.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Panning</surname><given-names>M.</given-names></name><name><surname>Kolesnikova</surname><given-names>L.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030747</pub-id><pub-id pub-id-type="pmid">12690091</pub-id></element-citation></ref><ref id="B10-ijerph-17-05648"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>Van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211721</pub-id><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="B11-ijerph-17-05648"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>38</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="B12-ijerph-17-05648"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Stratton</surname><given-names>C.W.</given-names></name><name><surname>Tang</surname><given-names>Y.W.</given-names></name></person-group><article-title>Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>401</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1002/jmv.25678</pub-id><?supplied-pmid 31950516?><pub-id pub-id-type="pmid">31950516</pub-id></element-citation></ref><ref id="B13-ijerph-17-05648"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses</collab></person-group><article-title>The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><?supplied-pmid 32123347?><pub-id pub-id-type="pmid">32123347</pub-id></element-citation></ref><ref id="B14-ijerph-17-05648"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Coronaviruses: An overview of their replication and pathogenesis</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1282</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmid">25720466</pub-id></element-citation></ref><ref id="B15-ijerph-17-05648"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashour</surname><given-names>H.M.</given-names></name><name><surname>Elkhatib</surname><given-names>W.F.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name><name><surname>Elshabrawy</surname><given-names>H.A.</given-names></name></person-group><article-title>Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>186</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9030186</pub-id></element-citation></ref><ref id="B16-ijerph-17-05648"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Lam</surname><given-names>C.S.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Tsang</surname><given-names>A.K.</given-names></name><name><surname>Lau</surname><given-names>J.H.</given-names></name><name><surname>Bai</surname><given-names>R.</given-names></name><name><surname>Teng</surname><given-names>J.L.</given-names></name><name><surname>Tsang</surname><given-names>C.C.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>3995</fpage><lpage>4008</lpage><pub-id pub-id-type="doi">10.1128/JVI.06540-11</pub-id><pub-id pub-id-type="pmid">22278237</pub-id></element-citation></ref><ref id="B17-ijerph-17-05648"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="B18-ijerph-17-05648"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>J.F.</given-names></name><name><surname>Gloza-Rausch</surname><given-names>F.</given-names></name><name><surname>Glende</surname><given-names>J.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Goettsche</surname><given-names>M.</given-names></name><name><surname>Seebens</surname><given-names>A.</given-names></name><name><surname>Niedrig</surname><given-names>M.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Yordanov</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genomic Characterization of Severe Acute Respiratory Syndrome-Related Coronavirus in European Bats and Classification of Coronaviruses Based on Partial RNA-Dependent RNA Polymerase Gene Sequences</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>11336</fpage><lpage>11349</lpage><pub-id pub-id-type="doi">10.1128/JVI.00650-10</pub-id><pub-id pub-id-type="pmid">20686038</pub-id></element-citation></ref><ref id="B19-ijerph-17-05648"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="B20-ijerph-17-05648"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Lai</surname><given-names>S.T.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Yam</surname><given-names>L.Y.</given-names></name><name><surname>Lim</surname><given-names>W.</given-names></name><name><surname>Nicholls</surname><given-names>J.</given-names></name><name><surname>Yee</surname><given-names>W.K.</given-names></name><name><surname>Yan</surname><given-names>W.W.</given-names></name><name><surname>Cheung</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>Coronavirus as a possible cause of severe acute respiratory syndrome</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13077-2</pub-id><pub-id pub-id-type="pmid">12711465</pub-id></element-citation></ref><ref id="B21-ijerph-17-05648"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>Wunderink</surname><given-names>R.G.</given-names></name></person-group><article-title>MERS, SARS and other coronaviruses as causes of pneumonia</article-title><source>Respirology</source><year>2018</year><volume>23</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/resp.13196</pub-id><?supplied-pmid 29052924?><pub-id pub-id-type="pmid">29052924</pub-id></element-citation></ref><ref id="B22-ijerph-17-05648"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>N.</given-names></name><name><surname>Dorigatti</surname><given-names>I.</given-names></name><name><surname>Cori</surname><given-names>A.</given-names></name><name><surname>Donnelly</surname><given-names>C.</given-names></name><name><surname>Riley</surname><given-names>S.</given-names></name><name><surname>Ferguson</surname><given-names>N.M.</given-names></name></person-group><article-title>Estimating the potential total number of novel Coronavirus cases in Wuhan City, China</article-title><source>Imp. Coll. Lond.</source><year>2020</year><pub-id pub-id-type="doi">10.25561/77150</pub-id></element-citation></ref><ref id="B23-ijerph-17-05648"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forni</surname><given-names>D.</given-names></name><name><surname>Cagliani</surname><given-names>R.</given-names></name><name><surname>Clerici</surname><given-names>M.</given-names></name><name><surname>Sironi</surname><given-names>M.</given-names></name></person-group><article-title>Molecular Evolution of Human Coronavirus Genomes</article-title><source>Trends Microbiol.</source><year>2017</year><volume>25</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.09.001</pub-id><?supplied-pmid 27743750?><pub-id pub-id-type="pmid">27743750</pub-id></element-citation></ref><ref id="B24-ijerph-17-05648"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>T.</given-names></name></person-group><article-title>A Review of Coronavirus Disease-2019 (COVID-19)</article-title><source>Indian J. Pediatr.</source><year>2020</year><volume>87</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s12098-020-03263-6</pub-id><?supplied-pmid 32166607?><pub-id pub-id-type="pmid">32166607</pub-id></element-citation></ref><ref id="B25-ijerph-17-05648"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses</article-title><source>Trends Microbiol.</source><year>2016</year><volume>24</volume><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2016.03.003</pub-id><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="B26-ijerph-17-05648"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi&#x00142;ek</surname><given-names>J.</given-names></name><name><surname>Blicharz-Doma&#x00144;ska</surname><given-names>K.</given-names></name></person-group><article-title>Coronaviruses in Avian Species&#x02014;Review with Focus on Epidemiology and Diagnosis in Wild Birds</article-title><source>J. Vet. Res.</source><year>2018</year><volume>62</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.2478/jvetres-2018-0035</pub-id><pub-id pub-id-type="pmid">30584600</pub-id></element-citation></ref><ref id="B27-ijerph-17-05648"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak</article-title><source>Curr. Biol.</source><year>2020</year><volume>30</volume><fpage>1346</fpage><lpage>1351.e2</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2020.03.022</pub-id><pub-id pub-id-type="pmid">32197085</pub-id></element-citation></ref><ref id="B28-ijerph-17-05648"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Coronavirus disease 2019: What we know?</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1002/jmv.25766</pub-id><pub-id pub-id-type="pmid">32170865</pub-id></element-citation></ref><ref id="B29-ijerph-17-05648"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlottau</surname><given-names>K.</given-names></name><name><surname>Rissmann</surname><given-names>M.</given-names></name><name><surname>Graaf</surname><given-names>A.</given-names></name><name><surname>Sch&#x000f6;n</surname><given-names>J.</given-names></name><name><surname>Sehl</surname><given-names>J.</given-names></name><name><surname>Wylezich</surname><given-names>C.</given-names></name><name><surname>H&#x000f6;per</surname><given-names>D.</given-names></name><name><surname>Mettenleiter</surname><given-names>T.C.</given-names></name><name><surname>Balkema-Buschmann</surname><given-names>A.</given-names></name><name><surname>Harder</surname><given-names>T.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: An experimental transmission study</article-title><source>Lancet Microbe</source><year>2020</year><volume>20</volume><pub-id pub-id-type="doi">10.1016/S2666-5247(20)30089-6</pub-id></element-citation></ref><ref id="B30-ijerph-17-05648"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Madani</surname><given-names>T.A.</given-names></name><name><surname>Ntoumi</surname><given-names>F.</given-names></name><name><surname>Kock</surname><given-names>R.</given-names></name><name><surname>Dar</surname><given-names>O.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Mchugh</surname><given-names>T.D.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health&#x02014;The latest 2019 novel coronavirus outbreak in Wuhan, China</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>91</volume><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.009</pub-id><pub-id pub-id-type="pmid">31953166</pub-id></element-citation></ref><ref id="B31-ijerph-17-05648"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Hoek</surname><given-names>L.</given-names></name><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Jebbink</surname><given-names>M.F.</given-names></name><name><surname>Vermeulen-Oost</surname><given-names>W.</given-names></name><name><surname>Berkhout</surname><given-names>R.J.</given-names></name><name><surname>Wolthers</surname><given-names>K.C.</given-names></name><name><surname>Wertheim-van Dillen</surname><given-names>P.M.</given-names></name><name><surname>Kaandorp</surname><given-names>J.</given-names></name><name><surname>Spaargaren</surname><given-names>J.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name></person-group><article-title>Identification of a new human coronavirus</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1038/nm1024</pub-id><pub-id pub-id-type="pmid">15034574</pub-id></element-citation></ref><ref id="B32-ijerph-17-05648"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name><name><surname>van der Hoek</surname><given-names>L.</given-names></name></person-group><article-title>Identification of new human coronaviruses</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2007</year><volume>5</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1586/14787210.5.2.245</pub-id><?supplied-pmid 17402839?><pub-id pub-id-type="pmid">17402839</pub-id></element-citation></ref><ref id="B33-ijerph-17-05648"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>M.</given-names></name><name><surname>Ruggiero</surname><given-names>A.</given-names></name><name><surname>Squeglia</surname><given-names>F.</given-names></name><name><surname>Maga</surname><given-names>G.</given-names></name><name><surname>Berisio</surname><given-names>R.</given-names></name></person-group><article-title>A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>1267</elocation-id><pub-id pub-id-type="doi">10.3390/cells9051267</pub-id><?supplied-pmid 32443810?><pub-id pub-id-type="pmid">32443810</pub-id></element-citation></ref><ref id="B34-ijerph-17-05648"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D.X.</given-names></name><name><surname>Fung</surname><given-names>T.S.</given-names></name><name><surname>Chong</surname><given-names>K.K.</given-names></name><name><surname>Shukla</surname><given-names>A.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group><article-title>Accessory proteins of SARS-CoV and other coronaviruses</article-title><source>Antivir. Res.</source><year>2014</year><volume>109</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.06.013</pub-id><pub-id pub-id-type="pmid">24995382</pub-id></element-citation></ref><ref id="B35-ijerph-17-05648"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>From SARS to MERS, Thrusting Coronaviruses into the Spotlight</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.3390/v11010059</pub-id><?supplied-pmid 30646565?><pub-id pub-id-type="pmid">30646565</pub-id></element-citation></ref><ref id="B36-ijerph-17-05648"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e1;ez-Santos</surname><given-names>Y.M.</given-names></name><name><surname>St John</surname><given-names>S.E.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name></person-group><article-title>The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds</article-title><source>Antivir. Res.</source><year>2015</year><volume>115</volume><fpage>21</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2014.12.015</pub-id><?supplied-pmid 25554382?><pub-id pub-id-type="pmid">25554382</pub-id></element-citation></ref><ref id="B37-ijerph-17-05648"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id><?supplied-pmid 31987001?><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="B38-ijerph-17-05648"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nal</surname><given-names>B.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Siu</surname><given-names>L.</given-names></name><name><surname>Tse</surname><given-names>J.</given-names></name><name><surname>Chu</surname><given-names>K.</given-names></name><name><surname>Kam</surname><given-names>J.</given-names></name><name><surname>Staropoli</surname><given-names>I.</given-names></name><name><surname>Crescenzo-Chaigne</surname><given-names>B.</given-names></name><name><surname>Escriou</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E</article-title><source>J. Gen. Virol.</source><year>2005</year><volume>86</volume><fpage>1423</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1099/vir.0.80671-0</pub-id><pub-id pub-id-type="pmid">15831954</pub-id></element-citation></ref><ref id="B39-ijerph-17-05648"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P.S.</given-names></name></person-group><article-title>The molecular biology of coronaviruses</article-title><source>Adv. Virus Res.</source><year>2006</year><volume>66</volume><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(06)66005-3</pub-id><pub-id pub-id-type="pmid">16877062</pub-id></element-citation></ref><ref id="B40-ijerph-17-05648"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>K.R.</given-names></name><name><surname>Koetzner</surname><given-names>C.A.</given-names></name><name><surname>Masters</surname><given-names>P.S.</given-names></name></person-group><article-title>Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>7221</fpage><lpage>7234</lpage><pub-id pub-id-type="doi">10.1128/JVI.00440-09</pub-id><pub-id pub-id-type="pmid">19420077</pub-id></element-citation></ref><ref id="B41-ijerph-17-05648"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>Y.L.</given-names></name><name><surname>Teoh</surname><given-names>K.T.</given-names></name><name><surname>Lo</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>C.M.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Escriou</surname><given-names>N.</given-names></name><name><surname>Tsao</surname><given-names>S.W.</given-names></name><name><surname>Nicholls</surname><given-names>J.M.</given-names></name><name><surname>Altmeyer</surname><given-names>R.</given-names></name><name><surname>Peiris</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>11318</fpage><lpage>11330</lpage><pub-id pub-id-type="doi">10.1128/JVI.01052-08</pub-id><?supplied-pmid 18753196?><pub-id pub-id-type="pmid">18753196</pub-id></element-citation></ref><ref id="B42-ijerph-17-05648"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The spike protein of SARS-CoV&#x02014;A target for vaccine and therapeutic development</article-title><source>Nat. Rev. Microbiol.</source><year>2009</year><volume>7</volume><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><?supplied-pmid 19198616?><pub-id pub-id-type="pmid">19198616</pub-id></element-citation></ref><ref id="B43-ijerph-17-05648"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>M.A.</given-names></name><name><surname>Jones</surname><given-names>S.J.</given-names></name><name><surname>Astell</surname><given-names>C.R.</given-names></name><name><surname>Holt</surname><given-names>R.A.</given-names></name><name><surname>Brooks-Wilson</surname><given-names>A.</given-names></name><name><surname>Butterfield</surname><given-names>Y.S.</given-names></name><name><surname>Khattra</surname><given-names>J.</given-names></name><name><surname>Asano</surname><given-names>J.K.</given-names></name><name><surname>Barber</surname><given-names>S.A.</given-names></name><name><surname>Chan</surname><given-names>S.Y.</given-names></name><etal/></person-group><article-title>The Genome sequence of the SARS-associated coronavirus</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1399</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1126/science.1085953</pub-id><?supplied-pmid 12730501?><pub-id pub-id-type="pmid">12730501</pub-id></element-citation></ref><ref id="B44-ijerph-17-05648"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rota</surname><given-names>P.A.</given-names></name><name><surname>Oberste</surname><given-names>M.S.</given-names></name><name><surname>Monroe</surname><given-names>S.S.</given-names></name><name><surname>Nix</surname><given-names>W.A.</given-names></name><name><surname>Campagnoli</surname><given-names>R.</given-names></name><name><surname>Icenogle</surname><given-names>J.P.</given-names></name><name><surname>Pe&#x000f1;aranda</surname><given-names>S.</given-names></name><name><surname>Bankamp</surname><given-names>B.</given-names></name><name><surname>Maher</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1394</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1126/science.1085952</pub-id><?supplied-pmid 12730500?><pub-id pub-id-type="pmid">12730500</pub-id></element-citation></ref><ref id="B45-ijerph-17-05648"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Bredenbeek</surname><given-names>P.J.</given-names></name><name><surname>Dobbe</surname><given-names>J.C.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Rozanov</surname><given-names>M.</given-names></name><name><surname>Spaan</surname><given-names>W.J.</given-names></name><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name></person-group><article-title>Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage</article-title><source>J. Mol. Biol.</source><year>2003</year><volume>331</volume><fpage>991</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(03)00865-9</pub-id><pub-id pub-id-type="pmid">12927536</pub-id></element-citation></ref><ref id="B46-ijerph-17-05648"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Groot</surname><given-names>R.J.</given-names></name></person-group><article-title>Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses</article-title><source>Glycoconj. J.</source><year>2006</year><volume>23</volume><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s10719-006-5438-8</pub-id><pub-id pub-id-type="pmid">16575523</pub-id></element-citation></ref><ref id="B47-ijerph-17-05648"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausegger</surname><given-names>A.</given-names></name><name><surname>Strobl</surname><given-names>B.</given-names></name><name><surname>Regl</surname><given-names>G.</given-names></name><name><surname>Kaser</surname><given-names>A.</given-names></name><name><surname>Luytjes</surname><given-names>W.</given-names></name><name><surname>Vlasak</surname><given-names>R.</given-names></name></person-group><article-title>Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus</article-title><source>J. Virol.</source><year>1999</year><volume>73</volume><fpage>3737</fpage><lpage>3743</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.5.3737-3743.1999</pub-id><pub-id pub-id-type="pmid">10196267</pub-id></element-citation></ref><ref id="B48-ijerph-17-05648"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>S.R.</given-names></name><name><surname>Navas-Martin</surname><given-names>S.</given-names></name></person-group><article-title>Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2005</year><volume>69</volume><fpage>635</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1128/MMBR.69.4.635-664.2005</pub-id><pub-id pub-id-type="pmid">16339739</pub-id></element-citation></ref><ref id="B49-ijerph-17-05648"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>325</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id><pub-id pub-id-type="pmid">32035028</pub-id></element-citation></ref><ref id="B50-ijerph-17-05648"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shereen</surname><given-names>M.A.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Kazmi</surname><given-names>A.</given-names></name><name><surname>Bashir</surname><given-names>N.</given-names></name><name><surname>Siddique</surname><given-names>R.</given-names></name></person-group><article-title>COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses</article-title><source>J. Adv. Res.</source><year>2020</year><volume>24</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmid">32257431</pub-id></element-citation></ref><ref id="B51-ijerph-17-05648"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id><?supplied-pmid 31996437?><pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="B52-ijerph-17-05648"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="B53-ijerph-17-05648"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Niu</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Qiao</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><etal/></person-group><article-title>Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>894</fpage><lpage>904.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><?supplied-pmid 32275855?><pub-id pub-id-type="pmid">32275855</pub-id></element-citation></ref><ref id="B54-ijerph-17-05648"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>281</fpage><lpage>292.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="B55-ijerph-17-05648"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>Reeves</surname><given-names>J.D.</given-names></name><name><surname>Rennekamp</surname><given-names>A.J.</given-names></name><name><surname>Amberg</surname><given-names>S.M.</given-names></name><name><surname>Piefer</surname><given-names>A.J.</given-names></name><name><surname>Bates</surname><given-names>P.</given-names></name></person-group><article-title>Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>4240</fpage><lpage>4245</lpage><pub-id pub-id-type="doi">10.1073/pnas.0306446101</pub-id><?supplied-pmid 15010527?><pub-id pub-id-type="pmid">15010527</pub-id></element-citation></ref><ref id="B56-ijerph-17-05648"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>5498</fpage><lpage>5508</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.054</pub-id><pub-id pub-id-type="pmid">16725238</pub-id></element-citation></ref><ref id="B57-ijerph-17-05648"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>McGoogan</surname><given-names>J.M.</given-names></name></person-group><article-title>Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id></element-citation></ref><ref id="B58-ijerph-17-05648"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Smits</surname><given-names>S.L.</given-names></name><name><surname>Dekkers</surname><given-names>D.H.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Demmers</surname><given-names>J.A.</given-names></name><name><surname>Zaki</surname><given-names>A.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nature12005</pub-id><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="B59-ijerph-17-05648"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>E.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Weber</surname><given-names>F.</given-names></name></person-group><article-title>Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response</article-title><source>Adv. Virus Res.</source><year>2016</year><volume>96</volume><fpage>219</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/bs.aivir.2016.08.006</pub-id><pub-id pub-id-type="pmid">27712625</pub-id></element-citation></ref><ref id="B60-ijerph-17-05648"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>A.R.</given-names></name><name><surname>Erdogan</surname><given-names>A.</given-names></name><name><surname>Agaoglu</surname><given-names>P.M.</given-names></name><name><surname>Dineri</surname><given-names>Y.</given-names></name><name><surname>Cakirci</surname><given-names>A.Y.</given-names></name><name><surname>Senel</surname><given-names>M.E.</given-names></name><name><surname>Okyay</surname><given-names>R.A.</given-names></name><name><surname>Tasdogan</surname><given-names>A.M.</given-names></name></person-group><article-title>2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature</article-title><source>EJMO</source><year>2020</year><volume>4</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.14744/ejmo.2020.12220</pub-id></element-citation></ref><ref id="B61-ijerph-17-05648"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>C.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>A New Bat-HKU2-like Coronavirus in Swine, China, 2017</article-title><source>Emerg. Infect. Dis.</source><year>2017</year><volume>23</volume><fpage>1607</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.3201/eid2309.170915</pub-id><?supplied-pmid 28654418?><pub-id pub-id-type="pmid">28654418</pub-id></element-citation></ref><ref id="B62-ijerph-17-05648"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>Y.L.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Discovery of a novel swine enteric alphacoronavirus (SeACoV) in southern China</article-title><source>Vet. Microbiol.</source><year>2017</year><volume>211</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2017.09.020</pub-id><?supplied-pmid 29102111?><pub-id pub-id-type="pmid">29102111</pub-id></element-citation></ref><ref id="B63-ijerph-17-05648"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Bat-to-human: Spike features determining &#x02018;host jump&#x02019; of coronaviruses SARS-CoV, MERS-CoV, and beyond</article-title><source>Trends Microbiol.</source><year>2015</year><volume>23</volume><fpage>468</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2015.06.003</pub-id><?supplied-pmid 26206723?><pub-id pub-id-type="pmid">26206723</pub-id></element-citation></ref><ref id="B64-ijerph-17-05648"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>B.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>You</surname><given-names>B.</given-names></name><etal/></person-group><article-title>SARS-associated coronavirus transmitted from human to pig</article-title><source>Emerg. Infect. Dis.</source><year>2005</year><volume>11</volume><fpage>446</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.3201/eid1103.040824</pub-id><?supplied-pmid 15757562?><pub-id pub-id-type="pmid">15757562</pub-id></element-citation></ref><ref id="B65-ijerph-17-05648"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergara-Alert</surname><given-names>J.</given-names></name><name><surname>van den Brand</surname><given-names>J.M.</given-names></name><name><surname>Widagdo</surname><given-names>W.</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>M.</given-names></name><name><surname>Raj</surname><given-names>S.</given-names></name><name><surname>Schipper</surname><given-names>D.</given-names></name><name><surname>Solanes</surname><given-names>D.</given-names></name><name><surname>Cord&#x000f3;n</surname><given-names>I.</given-names></name><name><surname>Bensaid</surname><given-names>A.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus</article-title><source>Emerg. Infect. Dis.</source><year>2017</year><volume>23</volume><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.3201/eid2302.161239</pub-id><pub-id pub-id-type="pmid">27901465</pub-id></element-citation></ref><ref id="B66-ijerph-17-05648"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>W.J.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Jin</surname><given-names>T.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Ji</surname><given-names>W.</given-names></name><name><surname>Jia</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A Bat-Derived Putative Cross-Family Recombinant Coronavirus with a Reovirus Gene</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005883</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005883</pub-id><pub-id pub-id-type="pmid">27676249</pub-id></element-citation></ref><ref id="B67-ijerph-17-05648"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>P.</given-names></name><name><surname>Forster</surname><given-names>L.</given-names></name><name><surname>Renfrew</surname><given-names>C.</given-names></name><name><surname>Forster</surname><given-names>M.</given-names></name></person-group><article-title>Phylogenetic network analysis of SARS-CoV-2 genomes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>9241</fpage><lpage>9243</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004999117</pub-id><pub-id pub-id-type="pmid">32269081</pub-id></element-citation></ref><ref id="B68-ijerph-17-05648"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Kuhn</surname><given-names>J.H.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Huang</surname><given-names>I.C.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2</article-title><source>EMBO J.</source><year>2005</year><volume>24</volume><fpage>1634</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600640</pub-id><pub-id pub-id-type="pmid">15791205</pub-id></element-citation></ref><ref id="B69-ijerph-17-05648"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>H.P.</given-names></name><name><surname>Look</surname><given-names>D.C.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Hickey</surname><given-names>M.</given-names></name><name><surname>Pewe</surname><given-names>L.</given-names></name><name><surname>Netland</surname><given-names>J.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name></person-group><article-title>ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>14614</fpage><lpage>14621</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.23.14614-14621.2005</pub-id><pub-id pub-id-type="pmid">16282461</pub-id></element-citation></ref><ref id="B70-ijerph-17-05648"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>J.T.</given-names></name><name><surname>Serrano</surname><given-names>M.L.</given-names></name><name><surname>Pujol</surname><given-names>F.H.</given-names></name><name><surname>Rangel</surname><given-names>H.R.</given-names></name></person-group><article-title>Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis</article-title><source>EXCLI J.</source><year>2020</year><volume>19</volume><pub-id pub-id-type="doi">10.17179/excli2020-1167</pub-id></element-citation></ref><ref id="B71-ijerph-17-05648"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>K.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Aihara</surname><given-names>H.</given-names></name><name><surname>Geng</surname><given-names>Q.</given-names></name><name><surname>Auerbach</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><?supplied-pmid 32225175?><pub-id pub-id-type="pmid">32225175</pub-id></element-citation></ref><ref id="B72-ijerph-17-05648"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciaglia</surname><given-names>E.</given-names></name><name><surname>Vecchione</surname><given-names>C.</given-names></name><name><surname>Puca</surname><given-names>A.A.</given-names></name></person-group><article-title>COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children</article-title><source>Front. Pediatr.</source><year>2020</year><volume>8</volume><fpage>206</fpage><pub-id pub-id-type="doi">10.3389/fped.2020.00206</pub-id><pub-id pub-id-type="pmid">32391299</pub-id></element-citation></ref><ref id="B73-ijerph-17-05648"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name></person-group><article-title>Contact Tracing: A game of big numbers in the time of COVID-19</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.2139/ssrn.3590183</pub-id></element-citation></ref><ref id="B74-ijerph-17-05648"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Ruan</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2001737</pub-id><pub-id pub-id-type="pmid">32074444</pub-id></element-citation></ref><ref id="B75-ijerph-17-05648"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrosillo</surname><given-names>N.</given-names></name><name><surname>Viceconte</surname><given-names>G.</given-names></name><name><surname>Ergonul</surname><given-names>O.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Petersen</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19, SARS and MERS: Are they closely related?</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.026</pub-id><?supplied-pmid 32234451?><pub-id pub-id-type="pmid">32234451</pub-id></element-citation></ref><ref id="B76-ijerph-17-05648"><label>76.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cascella</surname><given-names>M.</given-names></name><name><surname>Rajnik</surname><given-names>M.</given-names></name><name><surname>Cuomo</surname><given-names>A.</given-names></name><name><surname>Dulebohn</surname><given-names>S.C.</given-names></name><name><surname>Di Napoli</surname><given-names>R.</given-names></name></person-group><article-title>Features, Evaluation and Treatment Coronavirus (COVID-19)</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2020</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/32150360">http://www.ncbi.nlm.nih.gov/pubmed/32150360</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-04">(accessed on 4 July 2020)</date-in-citation></element-citation></ref><ref id="B77-ijerph-17-05648"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective</article-title><source>J. Med. Virol.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1002/jmv.25749</pub-id></element-citation></ref><ref id="B78-ijerph-17-05648"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothan</surname><given-names>H.A.</given-names></name><name><surname>Byrareddy</surname><given-names>S.N.</given-names></name></person-group><article-title>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak</article-title><source>J. Autoimmun.</source><year>2020</year><volume>109</volume><fpage>102433</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2020.102433</pub-id><pub-id pub-id-type="pmid">32113704</pub-id></element-citation></ref><ref id="B79-ijerph-17-05648"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampf</surname><given-names>G.</given-names></name><name><surname>Todt</surname><given-names>D.</given-names></name><name><surname>Pfaender</surname><given-names>S.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name></person-group><article-title>Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents</article-title><source>J. Hosp. Infect.</source><year>2020</year><volume>104</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2020.01.022</pub-id><pub-id pub-id-type="pmid">32035997</pub-id></element-citation></ref><ref id="B80-ijerph-17-05648"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>C.</given-names></name><name><surname>Kaushal</surname><given-names>S.</given-names></name><name><surname>Yeo</surname><given-names>D.</given-names></name></person-group><article-title>Enteric involvement of coronaviruses: Is faecal-oral transmission of SARS-CoV-2 possible?</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2020</year><volume>5</volume><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30048-0</pub-id><pub-id pub-id-type="pmid">32087098</pub-id></element-citation></ref><ref id="B81-ijerph-17-05648"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.W.</given-names></name><name><surname>Liu</surname><given-names>X.F.</given-names></name><name><surname>Jia</surname><given-names>Z.F.</given-names></name></person-group><article-title>2019-nCoV transmission through the ocular surface must not be ignored</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>e39</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30313-5</pub-id><pub-id pub-id-type="pmid">32035510</pub-id></element-citation></ref><ref id="B82-ijerph-17-05648"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association</collab></person-group><article-title>An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)</article-title><source>Zhonghua Liu Xing Bing Xue Za Zhi</source><year>2020</year><volume>41</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0254-6450.2020.02.002</pub-id><pub-id pub-id-type="pmid">32057211</pub-id></element-citation></ref><ref id="B83-ijerph-17-05648"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Gong</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30360-3</pub-id><pub-id pub-id-type="pmid">32151335</pub-id></element-citation></ref><ref id="B84-ijerph-17-05648"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.J.</given-names></name></person-group><article-title>Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1313</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2131</pub-id></element-citation></ref><ref id="B85-ijerph-17-05648"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>Y.X.</given-names></name><name><surname>Ng</surname><given-names>Y.L.</given-names></name><name><surname>Tam</surname><given-names>J.P.</given-names></name><name><surname>Liu</surname><given-names>D.X.</given-names></name></person-group><article-title>Human Coronaviruses: A Review of Virus-Host Interactions</article-title><source>Diseases</source><year>2016</year><volume>4</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.3390/diseases4030026</pub-id><?supplied-pmid 28933406?><pub-id pub-id-type="pmid">28933406</pub-id></element-citation></ref><ref id="B86-ijerph-17-05648"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan-Yeung</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>R.H.</given-names></name></person-group><article-title>SARS: Epidemiology</article-title><source>Respirology</source><year>2003</year><volume>8</volume><fpage>S9</fpage><lpage>S14</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1843.2003.00518.x</pub-id><?supplied-pmid 15018127?><pub-id pub-id-type="pmid">15018127</pub-id></element-citation></ref><ref id="B87-ijerph-17-05648"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gretebeck</surname><given-names>L.M.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Animal models for SARS and MERS coronaviruses</article-title><source>Curr. Opin. Virol.</source><year>2015</year><volume>13</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2015.06.009</pub-id><pub-id pub-id-type="pmid">26184451</pub-id></element-citation></ref><ref id="B88-ijerph-17-05648"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>T.A.</given-names></name></person-group><article-title>Outbreak of a novel coronavirus</article-title><source>Nat. Rev. Microbiol.</source><year>2020</year><volume>18</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.1038/s41579-020-0332-0</pub-id><pub-id pub-id-type="pmid">31988490</pub-id></element-citation></ref><ref id="B89-ijerph-17-05648"><label>89.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Health Commission of the People&#x02019;s Republic of China</collab></person-group><article-title>Pneumonia Epidemic Situation of New Coronavirus Infection on 23 January 2020</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/yjb/s3578/202001/5d19a4f6d3154b9fae328918ed2e3c8a.shtml">http://www.nhc.gov.cn/yjb/s3578/202001/5d19a4f6d3154b9fae328918ed2e3c8a.shtml</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-01-23">(accessed on 23 January 2020)</date-in-citation></element-citation></ref><ref id="B90-ijerph-17-05648"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogoch</surname><given-names>I.I.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Thomas-Bachli</surname><given-names>A.</given-names></name><name><surname>Huber</surname><given-names>C.</given-names></name><name><surname>Kraemer</surname><given-names>M.U.G.</given-names></name><name><surname>Khan</surname><given-names>K.</given-names></name></person-group><article-title>Pneumonia of unknown aetiology in Wuhan, China: Potential for international spread via commercial air travel</article-title><source>J. Travel Med.</source><year>2020</year><volume>27</volume><pub-id pub-id-type="doi">10.1093/jtm/taaa008</pub-id></element-citation></ref><ref id="B91-ijerph-17-05648"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCreary</surname><given-names>E.K.</given-names></name><name><surname>Pogue</surname><given-names>J.M.</given-names></name></person-group><article-title>Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options</article-title><source>Open Forum Infect. Dis.</source><year>2020</year><volume>7</volume><pub-id pub-id-type="doi">10.1093/ofid/ofaa105</pub-id></element-citation></ref><ref id="B92-ijerph-17-05648"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="B93-ijerph-17-05648"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z.J.</given-names></name><name><surname>Shan</surname><given-names>J.</given-names></name></person-group><article-title>2019 Novel coronavirus: Where we are and what we know</article-title><source>Infection</source><year>2020</year><volume>48</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/s15010-020-01401-y</pub-id><pub-id pub-id-type="pmid">32072569</pub-id></element-citation></ref><ref id="B94-ijerph-17-05648"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Chiu</surname><given-names>A.P.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>D.</given-names></name></person-group><article-title>Modeling the spread of Middle East respiratory syndrome coronavirus in Saudi Arabia</article-title><source>Stat. Methods Med. Res.</source><year>2018</year><volume>27</volume><fpage>1968</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1177/0962280217746442</pub-id><?supplied-pmid 29846148?><pub-id pub-id-type="pmid">29846148</pub-id></element-citation></ref><ref id="B95-ijerph-17-05648"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsitch</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>T.</given-names></name><name><surname>Cooper</surname><given-names>B.</given-names></name><name><surname>Robins</surname><given-names>J.M.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>James</surname><given-names>L.</given-names></name><name><surname>Gopalakrishna</surname><given-names>G.</given-names></name><name><surname>Chew</surname><given-names>S.K.</given-names></name><name><surname>Tan</surname><given-names>C.C.</given-names></name><name><surname>Samore</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Transmission dynamics and control of severe acute respiratory syndrome</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1966</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1126/science.1086616</pub-id><?supplied-pmid 12766207?><pub-id pub-id-type="pmid">12766207</pub-id></element-citation></ref><ref id="B96-ijerph-17-05648"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriyama</surname><given-names>M.</given-names></name><name><surname>Hugentobler</surname><given-names>W.J.</given-names></name><name><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Seasonality of Respiratory Viral Infections</article-title><source>Annu. Rev. Virol.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1146/annurev-virology-012420-022445</pub-id><?supplied-pmid 32196426?><pub-id pub-id-type="pmid">32196426</pub-id></element-citation></ref><ref id="B97-ijerph-17-05648"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Zhuang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name></person-group><article-title>Assessment of China&#x02019;s Offshore Wind Resources Based on the Integration of Multiple Satellite Data and Meteorological Data</article-title><source>Remote Sens.</source><year>2019</year><volume>11</volume><elocation-id>2680</elocation-id><pub-id pub-id-type="doi">10.3390/rs11222680</pub-id></element-citation></ref><ref id="B98-ijerph-17-05648"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>K.</given-names></name><name><surname>Feng</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Lv</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>High Temperature and High Humidity Reduce the Transmission of COVID-19</article-title><source>SSRN</source><year>2020</year><pub-id pub-id-type="doi">10.2139/ssrn.3551767</pub-id></element-citation></ref><ref id="B99-ijerph-17-05648"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>A.</given-names></name><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Temperature significant change COVID-19 transmission in 429 cities</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.22.20025791</pub-id></element-citation></ref><ref id="B100-ijerph-17-05648"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannister-Tyrrell</surname><given-names>M.</given-names></name><name><surname>Meyer</surname><given-names>A.</given-names></name><name><surname>Faverjon</surname><given-names>C.</given-names></name><name><surname>Cameron</surname><given-names>A.</given-names></name></person-group><article-title>Preliminary evidence that higher temperatures are associated with lower incidence of COVID-19, for cases reported globally up to 29 February 2020</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.18.20036731</pub-id></element-citation></ref><ref id="B101-ijerph-17-05648"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Jing</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Du</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries</article-title><source>Sci. Total Environ.</source><year>2020</year><volume>729</volume><fpage>139051</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.139051</pub-id><pub-id pub-id-type="pmid">32361460</pub-id></element-citation></ref><ref id="B102-ijerph-17-05648"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scafetta</surname><given-names>N.</given-names></name></person-group><article-title>Distribution of the SARS-CoV-2 Pandemic and Its Monthly Forecast Based on Seasonal Climate Patterns</article-title><source>Int. J. Environ. Res. Public Health</source><year>2020</year><volume>17</volume><elocation-id>3493</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17103493</pub-id></element-citation></ref><ref id="B103-ijerph-17-05648"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raines</surname><given-names>K.S.</given-names></name><name><surname>Doniach</surname><given-names>S.</given-names></name><name><surname>Bhanot</surname><given-names>G.</given-names></name></person-group><article-title>The transmission of SARS-CoV-2 is likely comodulated by temperature and by relative humidity</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.23.20111278</pub-id></element-citation></ref><ref id="B104-ijerph-17-05648"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majidi Nezhad</surname><given-names>M.</given-names></name><name><surname>Groppi</surname><given-names>D.</given-names></name><name><surname>Marzialetti</surname><given-names>P.</given-names></name><name><surname>Fusilli</surname><given-names>L.</given-names></name><name><surname>Laneve</surname><given-names>G.</given-names></name><name><surname>Cumo</surname><given-names>F.</given-names></name><name><surname>Astiasogarsia</surname><given-names>D.</given-names></name></person-group><article-title>Wind energy potential analysis using Sentinel-1 satellite: A review and a case study on Mediterranean islands</article-title><source>Renew. Sustain. Energy Rev.</source><year>2019</year><volume>109</volume><fpage>499</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.rser.2019.04.059</pub-id></element-citation></ref><ref id="B105-ijerph-17-05648"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>Q.</given-names></name></person-group><article-title>Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures</article-title><source>J. Med. Virol.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1002/jmv.25748</pub-id><?supplied-pmid 32134116?><pub-id pub-id-type="pmid">32134116</pub-id></element-citation></ref><ref id="B106-ijerph-17-05648"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>R.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Lau</surname><given-names>E.</given-names></name><name><surname>Wong</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="B107-ijerph-17-05648"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id></element-citation></ref><ref id="B108-ijerph-17-05648"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>S.</given-names></name><name><surname>Shaik Syed Ali</surname><given-names>P.</given-names></name><name><surname>Sheeza</surname><given-names>A.</given-names></name><name><surname>Hemalatha</surname><given-names>K.</given-names></name></person-group><article-title>COVID-19 (Novel Coronavirus 2019) -recent trends</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2020</year><volume>24</volume><fpage>2006</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.26355/eurrev_202002_20378</pub-id><pub-id pub-id-type="pmid">32141569</pub-id></element-citation></ref><ref id="B109-ijerph-17-05648"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Jin</surname><given-names>D.Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Presumed Asymptomatic Carrier Transmission of COVID-19</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1406</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2565</pub-id></element-citation></ref><ref id="B110-ijerph-17-05648"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>F.</given-names></name></person-group><article-title>Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1002/jmv.25689</pub-id><pub-id pub-id-type="pmid">31994742</pub-id></element-citation></ref><ref id="B111-ijerph-17-05648"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name></person-group><article-title>Return of the Coronavirus: 2019-nCoV</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>135</elocation-id><pub-id pub-id-type="doi">10.3390/v12020135</pub-id></element-citation></ref><ref id="B112-ijerph-17-05648"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>L.T.</given-names></name><name><surname>Nguyen</surname><given-names>T.V.</given-names></name><name><surname>Luong</surname><given-names>Q.C.</given-names></name><name><surname>Nguyen</surname><given-names>T.V.</given-names></name><name><surname>Nguyen</surname><given-names>H.T.</given-names></name><name><surname>Le</surname><given-names>H.Q.</given-names></name><name><surname>Nguyen</surname><given-names>T.T.</given-names></name><name><surname>Cao</surname><given-names>T.M.</given-names></name><name><surname>Pham</surname><given-names>Q.D.</given-names></name></person-group><article-title>Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>872</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2001272</pub-id><pub-id pub-id-type="pmid">31991079</pub-id></element-citation></ref><ref id="B113-ijerph-17-05648"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="B114-ijerph-17-05648"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name></person-group><article-title>Coronavirus disease 2019: Initial chest CT findings</article-title><source>Eur. Radiol.</source><year>2020</year><volume>30</volume><fpage>4398</fpage><lpage>4406</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-06816-7</pub-id><?supplied-pmid 32211963?><pub-id pub-id-type="pmid">32211963</pub-id></element-citation></ref><ref id="B115-ijerph-17-05648"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name></person-group><article-title>CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia</article-title><source>Radiology</source><year>2020</year><volume>295</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1148/radiol.2020200236</pub-id><?supplied-pmid 32003646?><pub-id pub-id-type="pmid">32003646</pub-id></element-citation></ref><ref id="B116-ijerph-17-05648"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>S.</given-names></name><name><surname>Abedi</surname><given-names>A.</given-names></name><name><surname>Balakrishnan</surname><given-names>S.</given-names></name><name><surname>Gholamrezanezhad</surname><given-names>A.</given-names></name></person-group><article-title>Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients</article-title><source>AJR Am. J. Roentgenol.</source><year>2020</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2214/AJR.20.23672</pub-id><?supplied-pmid 32478611?><pub-id pub-id-type="pmid">32478611</pub-id></element-citation></ref><ref id="B117-ijerph-17-05648"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Thomsen</surname><given-names>T.</given-names></name><name><surname>Sell</surname><given-names>N.</given-names></name><name><surname>Goldsmith</surname><given-names>A.J.</given-names></name></person-group><article-title>Abdominal and testicular pain: An atypical presentation of COVID-19</article-title><source>Am. J. Emerg. Med.</source><year>2020</year><volume>38</volume><fpage>1542.e1</fpage><lpage>1542.e3</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2020.03.052</pub-id><?supplied-pmid 32273141?><pub-id pub-id-type="pmid">32273141</pub-id></element-citation></ref><ref id="B118-ijerph-17-05648"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>H.S.</given-names></name><name><surname>Harwood</surname><given-names>R.</given-names></name></person-group><article-title>Atypical presentation of COVID-19 in a frail older person</article-title><source>Age Ageing</source><year>2020</year><pub-id pub-id-type="doi">10.1093/ageing/afaa068</pub-id><?supplied-pmid 32315386?><pub-id pub-id-type="pmid">32315386</pub-id></element-citation></ref><ref id="B119-ijerph-17-05648"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: An operatioal recommendation of Peking Union Medical College Hospital (V2.0)</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>582</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1735265</pub-id><pub-id pub-id-type="pmid">32172669</pub-id></element-citation></ref><ref id="B120-ijerph-17-05648"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Si</surname><given-names>H.R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="B121-ijerph-17-05648"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Landt</surname><given-names>O.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Molenkamp</surname><given-names>R.</given-names></name><name><surname>Meijer</surname><given-names>A.</given-names></name><name><surname>Chu</surname><given-names>D.K.</given-names></name><name><surname>Bleicker</surname><given-names>T.</given-names></name><name><surname>Br&#x000fc;nink</surname><given-names>S.</given-names></name><name><surname>Schneider</surname><given-names>J.</given-names></name><name><surname>Schmidt</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title><source>Eurosurveillance</source><year>2020</year><volume>25</volume><fpage>2000045</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id></element-citation></ref><ref id="B122-ijerph-17-05648"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Du</surname><given-names>R.H.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>X.S.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.Y.</given-names></name><name><surname>Xiao</surname><given-names>G.F.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>Z.L.</given-names></name><etal/></person-group><article-title>Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1729071</pub-id><pub-id pub-id-type="pmid">32065057</pub-id></element-citation></ref><ref id="B123-ijerph-17-05648"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>D.K.W.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>S.M.S.</given-names></name><name><surname>Hui</surname><given-names>K.P.Y.</given-names></name><name><surname>Krishnan</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ng</surname><given-names>D.Y.M.</given-names></name><name><surname>Wan</surname><given-names>C.K.C.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia</article-title><source>Clin. Chem.</source><year>2020</year><volume>66</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1093/clinchem/hvaa029</pub-id><?supplied-pmid 32031583?><pub-id pub-id-type="pmid">32031583</pub-id></element-citation></ref><ref id="B124-ijerph-17-05648"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farfour</surname><given-names>E.</given-names></name><name><surname>Lesprit</surname><given-names>P.</given-names></name><name><surname>Visseaux</surname><given-names>B.</given-names></name><name><surname>Pascreau</surname><given-names>T.</given-names></name><name><surname>Jolly</surname><given-names>E.</given-names></name><name><surname>Houhou</surname><given-names>N.</given-names></name><name><surname>Mazaux</surname><given-names>L.</given-names></name><name><surname>Asso-Bonnet</surname><given-names>M.</given-names></name><name><surname>Vasse</surname><given-names>M.</given-names></name><collab>SARS-CoV-2 Foch Hospital Study Group</collab></person-group><article-title>The Allplex 2019-nCoV (Seegene) assay: Which performances are for SARS-CoV-2 infection diagnosis? [published online ahead of print, 28 May 2020]</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1007/s10096-020-03930-8</pub-id></element-citation></ref><ref id="B125-ijerph-17-05648"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xing</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.11.20021493</pub-id></element-citation></ref><ref id="B126-ijerph-17-05648"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binnicker</surname><given-names>M.J.</given-names></name></person-group><article-title>Emergence of a Novel Coronavirus Disease (COVID-19) and the Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak</article-title><source>Clin. Chem.</source><year>2020</year><volume>66</volume><fpage>664</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1093/clinchem/hvaa071</pub-id><pub-id pub-id-type="pmid">32077933</pub-id></element-citation></ref><ref id="B127-ijerph-17-05648"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merindol</surname><given-names>N.</given-names></name><name><surname>P&#x000e9;pin</surname><given-names>G.</given-names></name><name><surname>Marchand</surname><given-names>C.</given-names></name><name><surname>Rheault</surname><given-names>M.</given-names></name><name><surname>Peterson</surname><given-names>C.</given-names></name><name><surname>Poirier</surname><given-names>A.</given-names></name><name><surname>Houle</surname><given-names>C.</given-names></name><name><surname>Germain</surname><given-names>H.</given-names></name><name><surname>Danylo</surname><given-names>A.</given-names></name></person-group><article-title>SAS-CoV-2 detection by direct rRT-PCR without RNA extraction</article-title><source>J. Clin. Virol.</source><year>2020</year><volume>128</volume><fpage>104423</fpage><pub-id pub-id-type="doi">10.1016/j.jcv.2020.104423</pub-id><pub-id pub-id-type="pmid">32416598</pub-id></element-citation></ref><ref id="B128-ijerph-17-05648"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>N.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Alwalid</surname><given-names>O.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name></person-group><article-title>Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30086-4</pub-id><pub-id pub-id-type="pmid">32105637</pub-id></element-citation></ref><ref id="B129-ijerph-17-05648"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Imaging of coronavirus disease 2019: A Chinese expert consensus statement</article-title><source>Eur. J. Radiol.</source><year>2020</year><volume>127</volume><fpage>109008</fpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2020.109008</pub-id><pub-id pub-id-type="pmid">32335426</pub-id></element-citation></ref><ref id="B130-ijerph-17-05648"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>F.</given-names></name><name><surname>Ye</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>P.</given-names></name><name><surname>Gui</surname><given-names>S.</given-names></name><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hesketh</surname><given-names>R.L.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19)</article-title><source>Radiology</source><year>2020</year><volume>295</volume><fpage>715</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020200370</pub-id><pub-id pub-id-type="pmid">32053470</pub-id></element-citation></ref><ref id="B131-ijerph-17-05648"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name></person-group><article-title>Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): A study of 63 patients in Wuhan, China</article-title><source>Eur. Radiol.</source><year>2020</year><volume>30</volume><fpage>3306</fpage><lpage>3309</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-06731-x</pub-id><pub-id pub-id-type="pmid">32055945</pub-id></element-citation></ref><ref id="B132-ijerph-17-05648"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Hou</surname><given-names>H.</given-names></name><name><surname>Zhan</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Lv</surname><given-names>W.</given-names></name><name><surname>Tao</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name></person-group><article-title>Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases</article-title><source>Radiology</source><year>2020</year><volume>296</volume><fpage>E32</fpage><lpage>E40</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020200642</pub-id><pub-id pub-id-type="pmid">32101510</pub-id></element-citation></ref><ref id="B133-ijerph-17-05648"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chassagnon</surname><given-names>G.</given-names></name><name><surname>Vakalopoulou</surname><given-names>M.</given-names></name><name><surname>Paragios</surname><given-names>N.</given-names></name><name><surname>Revel</surname><given-names>M.P.</given-names></name></person-group><article-title>Artificial intelligence applications for thoracic imaging</article-title><source>Eur. J. Radiol.</source><year>2020</year><volume>123</volume><fpage>108774</fpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2019.108774</pub-id><?supplied-pmid 31841881?><pub-id pub-id-type="pmid">31841881</pub-id></element-citation></ref><ref id="B134-ijerph-17-05648"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>R.</given-names></name><name><surname>Iwano</surname><given-names>S.</given-names></name><name><surname>Naganawa</surname><given-names>S.</given-names></name></person-group><article-title>A review on the use of artificial intelligence for medical imaging of the lungs of patients with coronavirus disease 2019</article-title><source>Diagn. Interv. Radiol.</source><year>2020</year><pub-id pub-id-type="doi">10.5152/dir.2019.20294</pub-id><?supplied-pmid 32436845?><pub-id pub-id-type="pmid">32436845</pub-id></element-citation></ref><ref id="B135-ijerph-17-05648"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Radiological role in the detection, diagnosis and monitoring for the coronavirus disease 2019 (COVID-19)</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2020</year><volume>24</volume><fpage>4523</fpage><lpage>4528</lpage><pub-id pub-id-type="doi">10.26355/eurrev_202004_21035</pub-id><pub-id pub-id-type="pmid">32373990</pub-id></element-citation></ref><ref id="B136-ijerph-17-05648"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>CT imaging changes of corona virus disease 2019 (COVID-19): A multi-center study in Southwest China</article-title><source>J. Transl. Med.</source><year>2020</year><volume>18</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s12967-020-02324-w</pub-id><?supplied-pmid 32252784?><pub-id pub-id-type="pmid">31900168</pub-id></element-citation></ref><ref id="B137-ijerph-17-05648"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>M.</given-names></name><name><surname>Bernheim</surname><given-names>A.</given-names></name><name><surname>Mei</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Fayad</surname><given-names>Z.A.</given-names></name><etal/></person-group><article-title>CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)</article-title><source>Radiology</source><year>2020</year><volume>295</volume><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020200230</pub-id><?supplied-pmid 32017661?><pub-id pub-id-type="pmid">32017661</pub-id></element-citation></ref><ref id="B138-ijerph-17-05648"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Lyu</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name></person-group><article-title>CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic suspects: A practical scoring method</article-title><source>BMC Pulm. Med.</source><year>2020</year><volume>20</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12890-020-1170-6</pub-id><?supplied-pmid 32381057?><pub-id pub-id-type="pmid">31900129</pub-id></element-citation></ref><ref id="B139-ijerph-17-05648"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>Q.X.</given-names></name><name><surname>Liu</surname><given-names>B.Z.</given-names></name><name><surname>Deng</surname><given-names>H.J.</given-names></name><name><surname>Wu</surname><given-names>G.C.</given-names></name><name><surname>Deng</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Y.K.</given-names></name><name><surname>Liao</surname><given-names>P.</given-names></name><name><surname>Qiu</surname><given-names>J.F.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>X.F.</given-names></name><etal/></person-group><article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title><source>Nat. Med.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1038/s41591-020-0897-1</pub-id></element-citation></ref><ref id="B140-ijerph-17-05648"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Xiong</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</article-title><source>J. Med. Virol.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1002/jmv.25727</pub-id></element-citation></ref><ref id="B141-ijerph-17-05648"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohmer</surname><given-names>N.</given-names></name><name><surname>Westhaus</surname><given-names>S.</given-names></name><name><surname>R&#x000fc;hl</surname><given-names>C.</given-names></name><name><surname>Ciesek</surname><given-names>S.</given-names></name><name><surname>Rabenau</surname><given-names>H.F.</given-names></name></person-group><article-title>Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays</article-title><source>J. Clin. Virol.</source><year>2020</year><volume>129</volume><fpage>104480</fpage><pub-id pub-id-type="doi">10.1016/j.jcv.2020.104480</pub-id><pub-id pub-id-type="pmid">32505777</pub-id></element-citation></ref><ref id="B142-ijerph-17-05648"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Dela Cruz</surname><given-names>C.S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa310</pub-id></element-citation></ref><ref id="B143-ijerph-17-05648"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Zeng</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>T.</given-names></name></person-group><article-title>Serum IgA, IgM, and IgG responses in COVID-19</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41423-020-0474-z</pub-id></element-citation></ref><ref id="B144-ijerph-17-05648"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>B.</given-names></name><name><surname>Wen</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Dan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Diagnosis of Acute Respiratory Syndrome Coronavirus 2 Infection by Detection of Nucleocapsid Protein</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.07.20032524</pub-id></element-citation></ref><ref id="B145-ijerph-17-05648"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name><name><surname>Meenakshisundaram</surname><given-names>S.</given-names></name><name><surname>Manickam</surname><given-names>M.</given-names></name></person-group><article-title>Recent discovery and development of inhibitors targeting coronaviruses</article-title><source>Drug Discov. Today</source><year>2020</year><volume>25</volume><fpage>668</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.01.015</pub-id><?supplied-pmid 32006468?><pub-id pub-id-type="pmid">32006468</pub-id></element-citation></ref><ref id="B146-ijerph-17-05648"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group><article-title>This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan</article-title><source>Nature</source><year>2020</year><volume>577</volume><fpage>607</fpage><pub-id pub-id-type="doi">10.1038/d41586-020-00190-6</pub-id><?supplied-pmid 31992886?><pub-id pub-id-type="pmid">31992886</pub-id></element-citation></ref><ref id="B147-ijerph-17-05648"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>Y.S.</given-names></name><name><surname>Sircar</surname><given-names>S.</given-names></name><name><surname>Bhat</surname><given-names>S.</given-names></name><name><surname>Sharun</surname><given-names>K.</given-names></name><name><surname>Dhama</surname><given-names>K.</given-names></name><name><surname>Dadar</surname><given-names>M.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Chaicumpa</surname><given-names>W.</given-names></name></person-group><article-title>Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments</article-title><source>Vet. Q.</source><year>2020</year><volume>40</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/01652176.2020.1727993</pub-id><pub-id pub-id-type="pmid">32036774</pub-id></element-citation></ref><ref id="B148-ijerph-17-05648"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaher</surname><given-names>N.H.</given-names></name><name><surname>Mostafa</surname><given-names>M.I.</given-names></name><name><surname>Altaher</surname><given-names>A.Y.</given-names></name></person-group><article-title>Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors</article-title><source>Acta Pharm.</source><year>2020</year><volume>70</volume><fpage>145</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.2478/acph-2020-0024</pub-id><pub-id pub-id-type="pmid">31955138</pub-id></element-citation></ref><ref id="B149-ijerph-17-05648"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Updated Approaches against SARS-CoV-2</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><pub-id pub-id-type="doi">10.1128/AAC.00483-20</pub-id></element-citation></ref><ref id="B150-ijerph-17-05648"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.L.</given-names></name><name><surname>Zhang</surname><given-names>A.H.</given-names></name><name><surname>Wang</surname><given-names>X.J.</given-names></name></person-group><article-title>Traditional Chinese medicine for COVID-19 treatment</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>155</volume><fpage>104743</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104743</pub-id><?supplied-pmid 32145402?><pub-id pub-id-type="pmid">32145402</pub-id></element-citation></ref><ref id="B151-ijerph-17-05648"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Yao</surname><given-names>C.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza</article-title><source>Biosci. Trends</source><year>2013</year><volume>7</volume><fpage>253</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.5582/bst.2013.v7.5.253</pub-id><?supplied-pmid 24241177?><pub-id pub-id-type="pmid">24241177</pub-id></element-citation></ref><ref id="B152-ijerph-17-05648"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.X.</given-names></name><name><surname>Li</surname><given-names>S.X.</given-names></name><name><surname>Zheng</surname><given-names>F.Y.</given-names></name></person-group><article-title>Application of in Vitro Bionic Digestion and Biomembrane Extraction for Metal Speciation Analysis, Bioavailability and Risk Assessment in Lianhua Qingwen Capsule</article-title><source>Zhongguo Zhong Yao Za Zhi</source><year>2014</year><volume>39</volume><fpage>2330</fpage><lpage>2335</lpage><pub-id pub-id-type="pmid">25244770</pub-id></element-citation></ref><ref id="B153-ijerph-17-05648"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment</article-title><source>Biosci. Trends</source><year>2020</year><volume>1</volume><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.5582/bst.2020.01030</pub-id><?supplied-pmid 32037389?><pub-id pub-id-type="pmid">32037389</pub-id></element-citation></ref><ref id="B154-ijerph-17-05648"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Donaldson</surname><given-names>E.F.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A decade after SARS: Strategies for controlling emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2013</year><volume>11</volume><fpage>836</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3143</pub-id><?supplied-pmid 24217413?><pub-id pub-id-type="pmid">24217413</pub-id></element-citation></ref><ref id="B155-ijerph-17-05648"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.Y.</given-names></name><name><surname>Kong</surname><given-names>W.P.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</article-title><source>Nature</source><year>2004</year><volume>428</volume><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/nature02463</pub-id><?supplied-pmid 15024391?><pub-id pub-id-type="pmid">15024391</pub-id></element-citation></ref><ref id="B156-ijerph-17-05648"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>SARS vaccine development</article-title><source>Emerg. Infect. Dis.</source><year>2005</year><volume>11</volume><fpage>1016</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.3201/1107.050219</pub-id><pub-id pub-id-type="pmid">16022774</pub-id></element-citation></ref><ref id="B157-ijerph-17-05648"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zai</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Cross-species transmission of the newly identified coronavirus 2019-nCoV</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/jmv.25682</pub-id><?supplied-pmid 31967321?><pub-id pub-id-type="pmid">31967321</pub-id></element-citation></ref><ref id="B158-ijerph-17-05648"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widjaja</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>van Haperen</surname><given-names>R.</given-names></name><name><surname>Guti&#x000e9;rrez-&#x000c1;lvarez</surname><given-names>J.</given-names></name><name><surname>van Dieren</surname><given-names>B.</given-names></name><name><surname>Okba</surname><given-names>N.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name><name><surname>Grosveld</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Towards a solution to MERS: Protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein</article-title><source>Emerg. Microbes Infect.</source><year>2019</year><volume>8</volume><fpage>516</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1080/22221751.2019.1597644</pub-id><pub-id pub-id-type="pmid">30938227</pub-id></element-citation></ref><ref id="B159-ijerph-17-05648"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Penninger</surname><given-names>J.M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>N.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target</article-title><source>Intensive Care Med.</source><year>2020</year><volume>46</volume><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><pub-id pub-id-type="pmid">32125455</pub-id></element-citation></ref><ref id="B160-ijerph-17-05648"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname><given-names>R.L.</given-names></name></person-group><article-title>Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China</article-title><source>F1000Research</source><year>2020</year><volume>9</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.12688/f1000research.22211.2</pub-id><pub-id pub-id-type="pmid">32117569</pub-id></element-citation></ref><ref id="B161-ijerph-17-05648"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>382</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1729069</pub-id><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="B162-ijerph-17-05648"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name></person-group><article-title>Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><volume>17</volume><fpage>536</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0385-z</pub-id><pub-id pub-id-type="pmid">32132669</pub-id></element-citation></ref><ref id="B163-ijerph-17-05648"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurwitz</surname><given-names>D.</given-names></name></person-group><article-title>Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics</article-title><source>Drug Dev. Res.</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1002/ddr.21656</pub-id><?supplied-pmid 32129518?><pub-id pub-id-type="pmid">32129518</pub-id></element-citation></ref><ref id="B164-ijerph-17-05648"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Lan</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Ying</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><volume>17</volume><fpage>765</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0374-2</pub-id><?supplied-pmid 32047258?><pub-id pub-id-type="pmid">32047258</pub-id></element-citation></ref><ref id="B165-ijerph-17-05648"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Lan</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id><?supplied-pmid 32231345?><pub-id pub-id-type="pmid">32231345</pub-id></element-citation></ref><ref id="B166-ijerph-17-05648"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Teng</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0144475</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144475</pub-id><pub-id pub-id-type="pmid">26641892</pub-id></element-citation></ref><ref id="B167-ijerph-17-05648"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name></person-group><article-title>Analysis of the Genome Sequence and Prediction of B-Cell Epitopes of the Envelope Protein of Middle East Respiratory Syndrome-Coronavirus</article-title><source>IEEE/ACM Trans. Comput. Biol. Bioinform.</source><year>2018</year><volume>15</volume><fpage>1344</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1109/TCBB.2017.2702588</pub-id><pub-id pub-id-type="pmid">28574363</pub-id></element-citation></ref><ref id="B168-ijerph-17-05648"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="B169-ijerph-17-05648"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Inoue</surname><given-names>S.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Zhuang</surname><given-names>M.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Sugamura</surname><given-names>K.</given-names></name></person-group><article-title>Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>8722</fpage><lpage>8729</lpage><pub-id pub-id-type="doi">10.1128/JVI.00253-07</pub-id><pub-id pub-id-type="pmid">17522231</pub-id></element-citation></ref><ref id="B170-ijerph-17-05648"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group><article-title>SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway</article-title><source>Cell Res.</source><year>2008</year><volume>18</volume><fpage>290</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.15</pub-id><pub-id pub-id-type="pmid">18227861</pub-id></element-citation></ref><ref id="B171-ijerph-17-05648"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name><name><surname>Tucker</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Oechsle</surname><given-names>O.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name><name><surname>Stebbing</surname><given-names>J.</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>e30</fpage><lpage>e31</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30304-4</pub-id><pub-id pub-id-type="pmid">32032529</pub-id></element-citation></ref><ref id="B172-ijerph-17-05648"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neveu</surname><given-names>G.</given-names></name><name><surname>Ziv-Av</surname><given-names>A.</given-names></name><name><surname>Barouch-Bentov</surname><given-names>R.</given-names></name><name><surname>Berkerman</surname><given-names>E.</given-names></name><name><surname>Mulholland</surname><given-names>J.</given-names></name><name><surname>Einav</surname><given-names>S.</given-names></name></person-group><article-title>AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>4387</fpage><lpage>4404</lpage><pub-id pub-id-type="doi">10.1128/JVI.02705-14</pub-id><pub-id pub-id-type="pmid">25653444</pub-id></element-citation></ref><ref id="B173-ijerph-17-05648"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Boelaert</surname><given-names>J.R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name><name><surname>Majori</surname><given-names>G.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: An old drug against today&#x02019;s diseases?</article-title><source>Lancet Infect. Dis.</source><year>2003</year><volume>3</volume><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(03)00806-5</pub-id><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="B174-ijerph-17-05648"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Cui</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>E.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><etal/></person-group><article-title>In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></element-citation></ref><ref id="B175-ijerph-17-05648"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Won</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name><name><surname>Montgomery</surname><given-names>S.A.</given-names></name><name><surname>Hogg</surname><given-names>A.</given-names></name><name><surname>Babusis</surname><given-names>D.</given-names></name><name><surname>Clarke</surname><given-names>M.O.</given-names></name><etal/></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id><?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31911652</pub-id></element-citation></ref><ref id="B176-ijerph-17-05648"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Zou</surname><given-names>Q.</given-names></name></person-group><article-title>Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening</article-title><source>BioRxiv</source><year>2020</year><volume>1</volume><pub-id pub-id-type="doi">10.1101/2020.01.28.922922</pub-id></element-citation></ref><ref id="B177-ijerph-17-05648"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.W.</given-names></name><name><surname>Yiu</surname><given-names>C.B.</given-names></name><name><surname>Wong</surname><given-names>K.Y.</given-names></name></person-group><article-title>Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates</article-title><source>F1000Research</source><year>2020</year><volume>9</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.12688/f1000research.22457.2</pub-id><pub-id pub-id-type="pmid">32194944</pub-id></element-citation></ref><ref id="B178-ijerph-17-05648"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>M.A.</given-names></name></person-group><article-title>Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><pub-id pub-id-type="doi">10.1128/AAC.00399-20</pub-id></element-citation></ref><ref id="B179-ijerph-17-05648"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="B180-ijerph-17-05648"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T.M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Pandolfi</surname><given-names>P.P.</given-names></name></person-group><article-title>Virus against virus: A potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>189</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0290-0</pub-id><pub-id pub-id-type="pmid">32071427</pub-id></element-citation></ref><ref id="B181-ijerph-17-05648"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zha</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Tefsen</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>French</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Villanueva</surname><given-names>E.V.</given-names></name></person-group><article-title>Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)</article-title><source>Med. J. Aust.</source><year>2020</year><volume>212</volume><fpage>416</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.5694/mja2.50577</pub-id><pub-id pub-id-type="pmid">32266987</pub-id></element-citation></ref><ref id="B182-ijerph-17-05648"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Fang</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name></person-group><article-title>Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia</article-title><source>Signal Transduct. Target Ther.</source><year>2020</year><volume>5</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/s41392-020-0127-9</pub-id><pub-id pub-id-type="pmid">32296011</pub-id></element-citation></ref><ref id="B183-ijerph-17-05648"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>C.D.</given-names></name><name><surname>Millar</surname><given-names>J.E.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name></person-group><article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>473</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30317-2</pub-id><pub-id pub-id-type="pmid">32043983</pub-id></element-citation></ref><ref id="B184-ijerph-17-05648"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>F.</given-names></name><name><surname>Fabbri</surname><given-names>L.</given-names></name><name><surname>Stewart</surname><given-names>I.</given-names></name><name><surname>Robinson</surname><given-names>K.</given-names></name><name><surname>Smyth</surname><given-names>A.R.</given-names></name><name><surname>Jenkins</surname><given-names>G.</given-names></name></person-group><article-title>A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.23.20076612</pub-id></element-citation></ref><ref id="B185-ijerph-17-05648"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. [published online ahead of print, 3 March 2020]</article-title><source>Virol. Sin.</source><year>2020</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s12250-020-00207-4</pub-id><pub-id pub-id-type="pmid">31916022</pub-id></element-citation></ref><ref id="B186-ijerph-17-05648"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R.S.</given-names></name><name><surname>Manson</surname><given-names>J.J.</given-names></name><collab>HLH Across Speciality Collaboration, UK</collab></person-group><article-title>COVID-19: Consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="B187-ijerph-17-05648"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Tocilizumab treatment in COVID-19: A single center experience</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>814</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1002/jmv.25801</pub-id><pub-id pub-id-type="pmid">32253759</pub-id></element-citation></ref><ref id="B188-ijerph-17-05648"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michot</surname><given-names>J.M.</given-names></name><name><surname>Albiges</surname><given-names>L.</given-names></name><name><surname>Chaput</surname><given-names>N.</given-names></name><name><surname>Saada</surname><given-names>V.</given-names></name><name><surname>Pommeret</surname><given-names>F.</given-names></name><name><surname>Griscelli</surname><given-names>F.</given-names></name><name><surname>Balleyguier</surname><given-names>C.</given-names></name><name><surname>Besse</surname><given-names>B.</given-names></name><name><surname>Marabelle</surname><given-names>A.</given-names></name><name><surname>Netzer</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: A case report</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>961</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.300</pub-id><pub-id pub-id-type="pmid">32247642</pub-id></element-citation></ref><ref id="B189-ijerph-17-05648"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>K.</given-names></name><name><surname>Tong</surname><given-names>F.</given-names></name><name><surname>Fei</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name></person-group><article-title>First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab</article-title><source>Blood Adv.</source><year>2020</year><volume>4</volume><fpage>1307</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020001907</pub-id><pub-id pub-id-type="pmid">32243501</pub-id></element-citation></ref><ref id="B190-ijerph-17-05648"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marano</surname><given-names>G.</given-names></name><name><surname>Vaglio</surname><given-names>S.</given-names></name><name><surname>Pupella</surname><given-names>S.</given-names></name><name><surname>Facco</surname><given-names>G.</given-names></name><name><surname>Catalano</surname><given-names>L.</given-names></name><name><surname>Liumbruno</surname><given-names>G.M.</given-names></name><name><surname>Grazzini</surname><given-names>G.</given-names></name></person-group><article-title>Convalescent plasma: New evidence for an old therapeutic tool?</article-title><source>Blood Transfus.</source><year>2016</year><volume>14</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2450/2015.0131-15</pub-id><pub-id pub-id-type="pmid">26674811</pub-id></element-citation></ref><ref id="B191-ijerph-17-05648"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Convalescent plasma as a potential therapy for COVID-19</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30141-9</pub-id><pub-id pub-id-type="pmid">32113510</pub-id></element-citation></ref><ref id="B192-ijerph-17-05648"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="B193-ijerph-17-05648"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name><surname>Al-Homoud</surname><given-names>A.H.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Remdesivir as a possible therapeutic option for the COVID-19</article-title><source>Travel Med. Infect. Dis.</source><year>2020</year><volume>34</volume><fpage>101615</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101615</pub-id><?supplied-pmid 32145386?><pub-id pub-id-type="pmid">32145386</pub-id></element-citation></ref><ref id="B194-ijerph-17-05648"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seesuay</surname><given-names>W.</given-names></name><name><surname>Jittavisutthikul</surname><given-names>S.</given-names></name><name><surname>Sae-Lim</surname><given-names>N.</given-names></name><name><surname>Sookrung</surname><given-names>N.</given-names></name><name><surname>Sakolvaree</surname><given-names>Y.</given-names></name><name><surname>Chaicumpa</surname><given-names>W.</given-names></name></person-group><article-title>Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism</article-title><source>Emerg. Microbes Infect.</source><year>2018</year><volume>7</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41426-018-0031-3</pub-id><?supplied-pmid 29568066?><pub-id pub-id-type="pmid">29323102</pub-id></element-citation></ref><ref id="B195-ijerph-17-05648"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>M.</given-names></name><name><surname>Cuenca</surname><given-names>J.</given-names></name><name><surname>Cruz</surname><given-names>F.F.</given-names></name><name><surname>Figueroa</surname><given-names>F.E.</given-names></name><name><surname>Rocco</surname><given-names>P.</given-names></name><name><surname>Weiss</surname><given-names>D.J.</given-names></name></person-group><article-title>Current status of cell-based therapies for respiratory virus infections: Applicability to COVID-19</article-title><source>Eur. Respir. J.</source><year>2020</year><volume>55</volume><fpage>2000858</fpage><pub-id pub-id-type="doi">10.1183/13993003.00858-2020</pub-id><?supplied-pmid 32265310?><pub-id pub-id-type="pmid">32265310</pub-id></element-citation></ref><ref id="B196-ijerph-17-05648"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connick</surname><given-names>P.</given-names></name><name><surname>Kolappan</surname><given-names>M.</given-names></name><name><surname>Crawley</surname><given-names>C.</given-names></name><name><surname>Webber</surname><given-names>D.J.</given-names></name><name><surname>Patani</surname><given-names>R.</given-names></name><name><surname>Michell</surname><given-names>A.W.</given-names></name><name><surname>Du</surname><given-names>M.Q.</given-names></name><name><surname>Luan</surname><given-names>S.L.</given-names></name><name><surname>Altmann</surname><given-names>D.R.</given-names></name><name><surname>Thompson</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>150</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(11)70305-2</pub-id><pub-id pub-id-type="pmid">22236384</pub-id></element-citation></ref><ref id="B197-ijerph-17-05648"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>J.G.</given-names></name><name><surname>Liu</surname><given-names>K.D.</given-names></name><name><surname>Zhuo</surname><given-names>H.</given-names></name><name><surname>Caballero</surname><given-names>L.</given-names></name><name><surname>McMillan</surname><given-names>M.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Cosgrove</surname><given-names>K.</given-names></name><name><surname>Vojnik</surname><given-names>R.</given-names></name><name><surname>Calfee</surname><given-names>C.S.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial</article-title><source>Lancet Respir. Med.</source><year>2015</year><volume>3</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70291-7</pub-id><pub-id pub-id-type="pmid">25529339</pub-id></element-citation></ref><ref id="B198-ijerph-17-05648"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari</surname><given-names>E.</given-names></name><name><surname>Ferrarotti</surname><given-names>I.</given-names></name><name><surname>Saracino</surname><given-names>L.</given-names></name><name><surname>Perteghella</surname><given-names>S.</given-names></name><name><surname>Torre</surname><given-names>M.L.</given-names></name><name><surname>Corsico</surname><given-names>A.G.</given-names></name></person-group><article-title>Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>924</elocation-id><pub-id pub-id-type="doi">10.3390/cells9040924</pub-id></element-citation></ref><ref id="B199-ijerph-17-05648"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashmi</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Murad</surname><given-names>M.H.</given-names></name><name><surname>Litzow</surname><given-names>M.R.</given-names></name><name><surname>Adams</surname><given-names>R.H.</given-names></name><name><surname>Ball</surname><given-names>L.M.</given-names></name><name><surname>Prasad</surname><given-names>V.K.</given-names></name><name><surname>Kebriaei</surname><given-names>P.</given-names></name><name><surname>Ringden</surname><given-names>O.</given-names></name></person-group><article-title>Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis</article-title><source>Lancet Haematol.</source><year>2016</year><volume>3</volume><fpage>e45</fpage><lpage>e52</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(15)00224-0</pub-id><pub-id pub-id-type="pmid">26765648</pub-id></element-citation></ref><ref id="B200-ijerph-17-05648"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Therapeutic Applications of Mesenchymal Stem Cells for Systemic Lupus Erythematosus</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1089</volume><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/5584_2018_212</pub-id><pub-id pub-id-type="pmid">29767288</pub-id></element-citation></ref><ref id="B201-ijerph-17-05648"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galipeau</surname><given-names>J.</given-names></name><name><surname>Sens&#x000e9;b&#x000e9;</surname><given-names>L.</given-names></name></person-group><article-title>Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities</article-title><source>Cell Stem Cell</source><year>2018</year><volume>22</volume><fpage>824</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.05.004</pub-id><pub-id pub-id-type="pmid">29859173</pub-id></element-citation></ref><ref id="B202-ijerph-17-05648"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>M.E.</given-names></name><name><surname>Fibbe</surname><given-names>W.E.</given-names></name></person-group><article-title>Mesenchymal stromal cells: Sensors and switchers of inflammation</article-title><source>Cell Stem Cell</source><year>2013</year><volume>13</volume><fpage>392</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.09.006</pub-id><pub-id pub-id-type="pmid">24094322</pub-id></element-citation></ref><ref id="B203-ijerph-17-05648"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopcraft</surname><given-names>S.E.</given-names></name><name><surname>Damania</surname><given-names>B.</given-names></name></person-group><article-title>Tumour viruses and innate immunity</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2017</year><volume>372</volume><fpage>20160267</fpage><pub-id pub-id-type="doi">10.1098/rstb.2016.0267</pub-id></element-citation></ref><ref id="B204-ijerph-17-05648"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Ren</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Shou</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells: A double-edged sword in regulating immune responses</article-title><source>Cell Death Differ.</source><year>2012</year><volume>19</volume><fpage>1505</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1038/cdd.2012.26</pub-id><pub-id pub-id-type="pmid">22421969</pub-id></element-citation></ref><ref id="B205-ijerph-17-05648"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>Q.</given-names></name><name><surname>Shan</surname><given-names>G.</given-names></name><name><surname>Meng</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia</article-title><source>Aging Dis.</source><year>2020</year><volume>11</volume><fpage>216</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.14336/AD.2020.0228</pub-id><?supplied-pmid 32257537?><pub-id pub-id-type="pmid">32257537</pub-id></element-citation></ref><ref id="B206-ijerph-17-05648"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment</article-title><source>Engineering</source><year>2020</year><volume>10</volume><pub-id pub-id-type="doi">10.1016/j.eng.2020.02.006</pub-id></element-citation></ref><ref id="B207-ijerph-17-05648"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Shi</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Dou</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Liao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-04-154138</pub-id><?supplied-pmid 18832657?><pub-id pub-id-type="pmid">18832657</pub-id></element-citation></ref><ref id="B208-ijerph-17-05648"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>M.X.</given-names></name><name><surname>Ang</surname><given-names>I.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Lewis</surname><given-names>R.F.</given-names></name><name><surname>Chen</surname><given-names>J.I.</given-names></name><name><surname>Gutierrez</surname><given-names>R.A.</given-names></name><name><surname>Gwee</surname><given-names>S.</given-names></name><name><surname>Chua</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>623</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9030623</pub-id><?supplied-pmid 32110875?><pub-id pub-id-type="pmid">32110875</pub-id></element-citation></ref><ref id="B209-ijerph-17-05648"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Potential interventions for novel coronavirus in China: A systematic review</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1002/jmv.25707</pub-id><pub-id pub-id-type="pmid">32052466</pub-id></element-citation></ref><ref id="B210-ijerph-17-05648"><label>210.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>CEPI</collab></person-group><article-title>CEPI to Fund Three Programmes to Develop Vaccines against the Novel Coronavirus, nCoV-2019</article-title><year>2020</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://cepi.net/news_cepi/cepi-to-fund-three-programmes-todevelop-vaccines-against-the-novel-coronavirus-ncov-2019/">https://cepi.net/news_cepi/cepi-to-fund-three-programmes-todevelop-vaccines-against-the-novel-coronavirus-ncov-2019/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-02-15">(accessed on 15 February 2020)</date-in-citation></element-citation></ref><ref id="B211-ijerph-17-05648"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Erdos</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Kenniston</surname><given-names>T.W.</given-names></name><name><surname>Balmert</surname><given-names>S.C.</given-names></name><name><surname>Carey</surname><given-names>C.D.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Epperly</surname><given-names>M.W.</given-names></name><name><surname>Klimstra</surname><given-names>W.B.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><year>2020</year><volume>55</volume><fpage>102743</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmid">32249203</pub-id></element-citation></ref><ref id="B212-ijerph-17-05648"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balmert</surname><given-names>S.C.</given-names></name><name><surname>Carey</surname><given-names>C.D.</given-names></name><name><surname>Falo</surname><given-names>G.D.</given-names></name><name><surname>Sethi</surname><given-names>S.K.</given-names></name><name><surname>Erdos</surname><given-names>G.</given-names></name><name><surname>Korkmaz</surname><given-names>E.</given-names></name><name><surname>Falo</surname><given-names>L.D.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination</article-title><source>J. Control. Release</source><year>2020</year><volume>317</volume><fpage>336</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.11.023</pub-id><pub-id pub-id-type="pmid">31756393</pub-id></element-citation></ref><ref id="B213-ijerph-17-05648"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Birchall</surname><given-names>J.C.</given-names></name><name><surname>Coulman</surname><given-names>S.A.</given-names></name><name><surname>Tatovic</surname><given-names>D.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>F.S.</given-names></name><name><surname>Dayan</surname><given-names>C.M.</given-names></name><name><surname>Hanna</surname><given-names>S.J.</given-names></name></person-group><article-title>Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes</article-title><source>J. Control. Release</source><year>2016</year><volume>223</volume><fpage>178</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.12.040</pub-id><pub-id pub-id-type="pmid">26739548</pub-id></element-citation></ref><ref id="B214-ijerph-17-05648"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabashima</surname><given-names>K.</given-names></name><name><surname>Honda</surname><given-names>T.</given-names></name><name><surname>Ginhoux</surname><given-names>F.</given-names></name><name><surname>Egawa</surname><given-names>G.</given-names></name></person-group><article-title>The immunological anatomy of the skin</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0084-5</pub-id><?supplied-pmid 30429578?><pub-id pub-id-type="pmid">30429578</pub-id></element-citation></ref><ref id="B215-ijerph-17-05648"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>A.R.</given-names></name><name><surname>Larregina</surname><given-names>A.T.</given-names></name></person-group><article-title>Professional antigen-presenting cells of the skin</article-title><source>Immunol. Res.</source><year>2006</year><volume>36</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1385/IR:36:1:127</pub-id><pub-id pub-id-type="pmid">17337773</pub-id></element-citation></ref><ref id="B216-ijerph-17-05648"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A.E.</given-names></name><name><surname>Rubin</surname><given-names>J.P.</given-names></name><name><surname>Erdos</surname><given-names>G.</given-names></name><name><surname>Tkacheva</surname><given-names>O.A.</given-names></name><name><surname>Mathers</surname><given-names>A.R.</given-names></name><name><surname>Zahorchak</surname><given-names>A.F.</given-names></name><name><surname>Thomson</surname><given-names>A.W.</given-names></name><name><surname>Falo</surname><given-names>L.D.</given-names><suffix>Jr.</suffix></name><name><surname>Larregina</surname><given-names>A.T.</given-names></name></person-group><article-title>CD4<sup>+</sup> T cell responses elicited by different subsets of human skin migratory dendritic cells</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>7905</fpage><lpage>7915</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.12.7905</pub-id><pub-id pub-id-type="pmid">16339526</pub-id></element-citation></ref><ref id="B217-ijerph-17-05648"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumpter</surname><given-names>T.L.</given-names></name><name><surname>Balmert</surname><given-names>S.C.</given-names></name><name><surname>Kaplan</surname><given-names>D.H.</given-names></name></person-group><article-title>Cutaneous immune responses mediated by dendritic cells and mast cells</article-title><source>JCI Insight</source><year>2019</year><volume>4</volume><fpage>e123947</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.123947</pub-id></element-citation></ref><ref id="B218-ijerph-17-05648"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>J.</given-names></name><name><surname>Prausnitz</surname><given-names>M.R.</given-names></name></person-group><article-title>Microneedle patches for vaccination in developing countries</article-title><source>J. Control. Release</source><year>2016</year><volume>240</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.11.019</pub-id><?supplied-pmid 26603347?><pub-id pub-id-type="pmid">26603347</pub-id></element-citation></ref><ref id="B219-ijerph-17-05648"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quaresma</surname><given-names>J.</given-names></name></person-group><article-title>Organization of the Skin Immune System and Compartmentalized Immune Responses in Infectious Diseases</article-title><source>Clin. Microbiol. Rev.</source><year>2019</year><volume>32</volume><pub-id pub-id-type="doi">10.1128/CMR.00034-18</pub-id><?supplied-pmid 31366611?><pub-id pub-id-type="pmid">31366611</pub-id></element-citation></ref><ref id="B220-ijerph-17-05648"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J.A.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Kaplan</surname><given-names>D.H.</given-names></name></person-group><article-title>Neuronal Regulation of Cutaneous Immunity</article-title><source>J. Immunol.</source><year>2020</year><volume>204</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1901109</pub-id><pub-id pub-id-type="pmid">31907268</pub-id></element-citation></ref><ref id="B221-ijerph-17-05648"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dicks</surname><given-names>M.D.</given-names></name><name><surname>Spencer</surname><given-names>A.J.</given-names></name><name><surname>Edwards</surname><given-names>N.J.</given-names></name><name><surname>Wadell</surname><given-names>G.</given-names></name><name><surname>Bojang</surname><given-names>K.</given-names></name><name><surname>Gilbert</surname><given-names>S.C.</given-names></name><name><surname>Hill</surname><given-names>A.V.</given-names></name><name><surname>Cottingham</surname><given-names>M.G.</given-names></name></person-group><article-title>A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e40385</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0040385</pub-id><pub-id pub-id-type="pmid">22808149</pub-id></element-citation></ref><ref id="B222-ijerph-17-05648"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alharbi</surname><given-names>N.K.</given-names></name><name><surname>Padron-Regalado</surname><given-names>E.</given-names></name><name><surname>Thompson</surname><given-names>C.P.</given-names></name><name><surname>Kupke</surname><given-names>A.</given-names></name><name><surname>Wells</surname><given-names>D.</given-names></name><name><surname>Sloan</surname><given-names>M.A.</given-names></name><name><surname>Grehan</surname><given-names>K.</given-names></name><name><surname>Temperton</surname><given-names>N.</given-names></name><name><surname>Lambe</surname><given-names>T.</given-names></name><name><surname>Warimwe</surname><given-names>G.</given-names></name><etal/></person-group><article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>3780</fpage><lpage>3788</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.032</pub-id><pub-id pub-id-type="pmid">28579232</pub-id></element-citation></ref><ref id="B223-ijerph-17-05648"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>J.M.</given-names></name><name><surname>Monogue</surname><given-names>M.L.</given-names></name><name><surname>Jodlowski</surname><given-names>T.Z.</given-names></name><name><surname>Cutrell</surname><given-names>J.B.</given-names></name></person-group><article-title>Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1824</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6019</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijerph-17-05648-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Classic subgroup clusters of coronaviruses within the family <italic>Coronaviridae</italic>, subfamily <italic>Orthocoronavirinae</italic> and the respective genera: <italic>Alphacoronavirus</italic>, <italic>Betacoronavirus</italic>, <italic>Gammacoronavirus</italic> and <italic>Deltacoronavirus</italic>.</p></caption><graphic xlink:href="ijerph-17-05648-g001"/></fig><fig id="ijerph-17-05648-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Origin and evolution of (<bold>A</bold>) SARS-CoV, (<bold>B</bold>) MERS-CoV and (<bold>C</bold>) SARS-CoV-2 in the various hosts. Initially all viruses existed in diverse bat species as CoV-related viruses (SARSr-CoV, MERSr-CoV and SARSr-CoV-2); sequential mutations and recombinations allow them to adapt to intermediate hosts and finally humans [<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>].</p></caption><graphic xlink:href="ijerph-17-05648-g002"/></fig><fig id="ijerph-17-05648-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Typical coronavirus virion structure and proteins. The coronavirus genome encodes a (S) spike glycoprotein, an (E) envelope glycoprotein, a (M) membrane glycoprotein, a (N) nucleocapsid phosphoprotein and a (HE) hemagglutinin-esterase glycoprotein.</p></caption><graphic xlink:href="ijerph-17-05648-g003"/></fig><fig id="ijerph-17-05648-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Graphic genome structures of SARS-CoV-2, SARS-CoV and MERS-CoV. Each coronavirus (CoV) genome is schematically represented in the order of 5&#x02032;-ORF1a-ORF1b-S-E-M-N-3&#x02032;. The coronavirus genomes encode two replicase polypeptides pp1a and pp1ab translated from ORF1a and ORF1b; four structural genes encoding for four structural proteins including (S) spike, (M) membrane, (E) envelope and (N) nucleocapsid proteins. The single-stranded RNA genomes of SARS-CoV-2 (~29.8 kb), SARS-CoV (~29.7 kb) and MERS-CoV (~30.1 kb) harbor two large genes, the ORF1a (red) and 1b (blue) genes encoding accessory genes (nsps 1&#x02013;16, shades of red and blue). Encoded nonstructural proteins: 16 nsps (nsp1-nsp16) in SARS-CoV-2, SARS-CoV and MERS-CoV. Along with structural proteins (S, E, M and N), the 3&#x02032;-terminus of the SARS-CoV-2 and SARS-CoV genomes contain eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and orf14 and 3a, 3b, p6, 7a, 7b, 8a, 8b and 9b, respectively) while MERS-CoV genome contains only five (3, 4a, 4b, 5 and 8b). The genes encoding accessory proteins are unique in different coronaviruses in terms of number, genomic organization, sequence and functions (data extracted from [<xref rid="B35-ijerph-17-05648" ref-type="bibr">35</xref>,<xref rid="B49-ijerph-17-05648" ref-type="bibr">49</xref>,<xref rid="B57-ijerph-17-05648" ref-type="bibr">57</xref>]).</p></caption><graphic xlink:href="ijerph-17-05648-g004"/></fig><fig id="ijerph-17-05648-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Monthly temperature (degree C) reanalysis maps using ECMWF dataset of all the world. The temperatures at 2-m height, obtained from ERA-interim datasets (<uri xlink:href="https://climatereanalyzer.org/">https://climatereanalyzer.org/</uri>), have been processed to extract monthly means maps for the period November 2019 to February 2020. ERA-interim is a global reanalysis of recorded climate observations over the past 3.5 decades. It is presented as a gridded data set at approximately 0.7 degrees spatial resolution and 37 atmospheric levels. ERA-interim is produced by the European Center for Medium-Range Weather Forecasts (ECMWF) (<uri xlink:href="https://climatereanalyzer.org/">https://climatereanalyzer.org/</uri>).</p></caption><graphic xlink:href="ijerph-17-05648-g005a"/><graphic xlink:href="ijerph-17-05648-g005b"/></fig><fig id="ijerph-17-05648-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Organ involvement confirmed by clinical features or bioptic sampling in COVID-19 patients (<bold>A</bold>). Table describing main observed disorders (<bold>B</bold>).</p></caption><graphic xlink:href="ijerph-17-05648-g006"/></fig><fig id="ijerph-17-05648-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Median times, in days, from the onset of symptoms to death, to hospitalization, from hospitalization to death with and without intensive care unit (ICU)-admittance (Report based on available data on July 9th, 2020 collected from Istituto Superiore di Sanit&#x000e0;, ISS).</p></caption><graphic xlink:href="ijerph-17-05648-g007"/></fig><fig id="ijerph-17-05648-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Schematic representation of SARS-CoV-2 infection and virus-induced human immune system response. Proposed drugs directed both towards specific SARS-CoV-2 molecular targets and biologic processes are highlighted: inhibitors of SARS-CoV-2 fusion/entry targeting ACE2 receptor, spike protein, TMPRSS2 or HR1 and HR2 epitopes and clathrin-mediated endocytosis (I); molecules against SARS-CoV-2 main protease (II); molecules against viral genome replication (III); CRISPR technologies targeting SARS-CoV-2 RNA genome (IV); modulators of SARS-CoV-2 induced inflammatory response (V) and human neutralizing antibodies (VI). ACE2, angiotensin-converting enzyme 2; TMPRSS2, type 2 transmembrane serine proteases; RdRp, RNA-dependent RNA polymerase; HR1, heptad repeat 1; HR2, heptad repeat 2; HR2P, heptad repeat 2-derived peptides; EK1, a modified OC43-HR2P peptide. Adapted from [<xref rid="B223-ijerph-17-05648" ref-type="bibr">223</xref>].</p></caption><graphic xlink:href="ijerph-17-05648-g008"/></fig><table-wrap id="ijerph-17-05648-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-05648-t001_Table 1</object-id><label>Table 1</label><caption><p>Host factors(s) involved in SARS-CoV, MERS-CoV and the SARS-CoV-2 replications [<xref rid="B4-ijerph-17-05648" ref-type="bibr">4</xref>,<xref rid="B15-ijerph-17-05648" ref-type="bibr">15</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Replication Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Host Receptor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Attachment and entry</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Human angiotensin-converting enzyme 2 (ACE2)</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV and most probably SARS-CoV-2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cellular receptor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Human dipeptidyl peptidase 4 (DPP4 or CD26)</td><td align="center" valign="middle" rowspan="1" colspan="1">MERS-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Cellular receptor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cathepsin L</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Cleave and activate S protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Furin</td><td align="center" valign="middle" rowspan="1" colspan="1">MERS-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Cleave and activate S protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TMPRSS11D</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Cleave and activate S protein</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFITM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV, MERS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Restrict virus entry</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Genome replication and transcription</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">GSK3</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Phosphorylate N protein and facilitate viral replication</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hnRNPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulate viral RNA synthesis</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Translation of structural proteins</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">N-linked glycosylation enzymes</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Modify S and M protein; N-linked glycosylation of the S protein facilitates lectin-mediated virion attachment and constitutes some neutralizing epitopes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ER chaperones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proper folding and maturation of S protein</td></tr></tbody></table></table-wrap><table-wrap id="ijerph-17-05648-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-05648-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparison of main features among SARS-CoV, MERS-CoV and SARS-CoV-2 [<xref rid="B24-ijerph-17-05648" ref-type="bibr">24</xref>,<xref rid="B76-ijerph-17-05648" ref-type="bibr">76</xref>,<xref rid="B86-ijerph-17-05648" ref-type="bibr">86</xref>,<xref rid="B88-ijerph-17-05648" ref-type="bibr">88</xref>,<xref rid="B93-ijerph-17-05648" ref-type="bibr">93</xref>,<xref rid="B94-ijerph-17-05648" ref-type="bibr">94</xref>,<xref rid="B95-ijerph-17-05648" ref-type="bibr">95</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Receptor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Host</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intermediate Host</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Incubation Period</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Cases</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Deaths</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fatality</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">R0</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACE2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Civets and raccoon dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">between 2 and 10 days and up to 14 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8098</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">916</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPP4 (CD26)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Camels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">between 2 and 14 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2494</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">858</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~35%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACE2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Manis javanica, others?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Current estimates between 2 and 10 days and up to 14 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,889,134 August 3rd, 2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Over 686,145 August 3rd, 2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~3.8% August 3rd, 2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;6.47</td></tr></tbody></table></table-wrap><table-wrap id="ijerph-17-05648-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-05648-t003_Table 3</object-id><label>Table 3</label><caption><p>Average humidity and temperature in 10 different cities in Europe and North Africa between November 2019 to March 2020. The first five cities represent significant communities where transmission of COVID-19 was reported, whereas the second 5 cities are expected to be less exposed to COVID-19 due to different weather conditions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">City</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Average Humidity (%)</th><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Temperature (&#x000b0;C)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nov.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dec.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jan.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feb.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mar.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nov.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dec.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jan.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feb.</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mar.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rome</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Paris</td><td align="center" valign="middle" rowspan="1" colspan="1">78</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td><td align="center" valign="middle" rowspan="1" colspan="1">79</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Madrid</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Milan</td><td align="center" valign="middle" rowspan="1" colspan="1">77</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lisbon</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">77</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rabat</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">69</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Algiers</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tunis</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tripoli</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td><td align="center" valign="middle" rowspan="1" colspan="1">83</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cairo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td></tr></tbody></table></table-wrap><table-wrap id="ijerph-17-05648-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">ijerph-17-05648-t004_Table 4</object-id><label>Table 4</label><caption><p>Clinical manifestations of COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Types</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Symptoms</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In 81% of all confirmed COVID-19 cases. Dry cough, mild fever, sore throat, nasal congestion, muscle pain, headache and malaise. Absence of serious symptoms like dyspnea, also the absence of radiograph features. It may rapidly deteriorate into severe or critical cases, non-pneumonia or mild pneumonia.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dry cough, tachypnea and shortness of breath.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute respiratory distress syndrome (ARDS), severe pneumonia, severe dyspnea, sepsis or septic shock, tachypnea (respiratory frequency) &#x02265; 30/min, blood oxygen saturation (SpO<sub>2</sub>) &#x02264; 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO<sub>2</sub>/FiO<sub>2</sub>) &#x0003c; 300, and/or lung infiltrates &#x0003e; 50% within 24 to 48 h. Fever can be absent or moderate.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Critical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In 5% of all confirmed COVID-19 cases. Respiratory failure, septic shock, RNAemia, cardiac injury and/or multiple organ dysfunction or failure. Case fatality rate is 49% (higher case fatality rate for patients with preexisting co-morbidities and lower-case fatality rate (0.9%) for patients without co-morbidities). Cardiovascular disease (10.5%), diabetes (7.3%), respiratory disease (6.5%), hypertension (6%) and oncological complications (5.6%).</td></tr></tbody></table></table-wrap></floats-group></article>